Weight Loss Market Size, Share, Forecast & Trends Analysis

The global weight loss market was valued at USD 97.50 billion in 2025. It is estimated at USD 113.00 billion in 2026 and is expected to reach USD 244.00 billion by 2036, growing at a CAGR of 8.0% over the 2026-2036 forecast period. This report assesses obesity epidemiology, treatment pathways, technology, the clinical pipeline, pricing and reimbursement, patent expiry, regulation, manufacturing capacity, and competition.

The study covers products and services used to achieve and keep clinically meaningful weight loss in people with overweight and obesity. It includes pharmacotherapy (GLP-1 drugs, dual and triple incretin agonists, oral small molecules, and older anti-obesity drugs), nutrition and meal replacement products and supplements, bariatric, endoscopic, and other devices, and services such as commercial programs, clinical nutrition, telehealth, and counseling. Value is measured at manufacturer and provider revenue and counts only the obesity-indicated share of incretin sales. Diabetes prescriptions, general fitness equipment, gym memberships, and surgical facility and professional fees are excluded.

The World Obesity Federation's World Obesity Atlas 2025 projects that adults with obesity will increase from 524 million in 2010 to 1.13 billion in 2030, and that those with class II obesity and above will rise from 157 million to 385 million. Drug sales show how fast treatment is scaling: Eli Lilly reported 2025 Zepbound revenue of USD 13.54 billion, up 175%, while Novo Nordisk's obesity care business posted DKK 59.90 billion in sales over January-September 2025. Even so, according to the American Society for Metabolic and Bariatric Surgery (ASMBS), 90% to 95% of non-diabetic patients with severe obesity still receive no treatment at all.

Market Dynamics

Rising obesity prevalence is the main driver, as it enlarges the treatable population faster than any therapy can shrink it. Incretin medicines deliver far more weight loss than diet and exercise alone and have brought obesity care into routine practice, while new insurance and public coverage is turning clinical need into paid demand. The recognition of obesity as a chronic, relapsing disease supports long-term therapy and the nutrition, monitoring, and behavioral services that go with it. With most severe obesity still untreated, each gain in access adds volume.

Value growth is held back by large price cuts negotiated by governments and payers, which lower revenue per patient far below list prices. Many patients stop therapy within the first year because of side effects, cost, or supply gaps, and most regain weight afterward. Peptide synthesis, sterile fill-finish, and injection device assembly take years to expand, so supply still decides which markets are served. Drug therapy is also replacing surgery: ASMBS data show bariatric procedures in a severe obesity cohort fell from 42,615 in 2023 to 33,429 in 2025. Key challenges include weak health system readiness, concerns over long-term safety and muscle loss, the spread of compounded and counterfeit products, and weight regain after treatment ends.

Oral small-molecule drugs offer the largest new opportunity, since they avoid injections and sterile manufacturing limits and can be priced for mass use. Public coverage is a second opportunity: under agreements announced in November 2025, Medicare is due to start paying for obesity drugs from mid-2026, and eligible patients will face a USD 50 monthly copay under the U.S. agreements. Further openings lie in high-protein and muscle-preserving nutrition for patients on therapy and in emerging markets, where semaglutide patent expiry from 2026 is expected to bring lower-cost supply. Key trends include the move from injectable to oral drugs, multi-pathway incretin combinations, telehealth models tied to prescribing, and the expansion of these drugs into cardiovascular, kidney, sleep apnea, and liver indications.

Segment Analysis

The report analyzes the market by offering, drug class, route of administration, intervention setting, payer, consumer demographic, distribution channel, and geography, helping stakeholders identify where treatment and spending are shifting.

By offering, the report covers four groups: weight loss pharmacotherapy, nutrition & meal replacement, devices & surgical products, and services & programs. Nutrition & meal replacement is expected to hold the largest share in 2026, because shakes, bars, weight-management foods, and supplements reach a far wider consumer base than prescription drugs and most people with obesity are still not under medical care. Pharmacotherapy is expected to grow at the highest CAGR, driven by the fast uptake of incretin medicines, as seen in Zepbound's revenue growth in 2025, and by expanding coverage. Device and surgical product sales are likely to grow the slowest of the four, as medicines replace procedures.

The drug class analysis covers GLP-1 receptor agonists (semaglutide, liraglutide, and others), dual & triple incretin agonists, amylin-based products and combinations, and older agents such as phentermine, naltrexone-bupropion, and orlistat. GLP-1 receptor agonists are expected to hold the largest share in 2026, reflecting the large prescribing base for semaglutide; Novo Nordisk reported Wegovy sales of DKK 57.24 billion in the first nine months of 2025, up 49%. Dual and triple incretin agonists are expected to grow at the highest CAGR, as acting on several pathways delivers greater weight loss and prescribers move quickly to the most effective agents. Older products lose ground fast, as shown by falling Saxenda sales.

By route of administration, the market is divided into injectable (weekly and daily subcutaneous) and oral (oral peptide and oral small molecule) products. Injectables are expected to account for the largest share in 2026, given the large base of patients already on weekly injections. Oral therapy is expected to grow at the highest CAGR, supported by patient preference for pills, simpler and more scalable manufacturing, and lower prices, as the U.S. pricing agreements put oral starting doses at USD 145 to USD 150 per month.

The intervention setting analysis spans self-directed & retail use, primary care, specialty obesity & endocrinology clinics, hospitals & surgical centers, and digital & telehealth services. Self-directed and retail use is expected to lead in 2026, as consumers buy nutrition, meal replacement, and supplement products on their own without clinical oversight, which matches the large untreated share of the obese population. Digital and telehealth is expected to grow at the highest CAGR, as subscription services bundle prescribing, dose titration, coaching, and refills and reach areas with few specialist clinics.

By payer, the report covers out-of-pocket, commercial insurance, public insurance & government programs (Medicare, Medicaid, and national health systems outside the U.S.), and employer-sponsored plans. Out-of-pocket spending is expected to hold the largest share in 2026, as consumers fund most nutrition and program costs and still pay directly for a large part of drug therapy. Public insurance and government programs are expected to grow at the highest CAGR, led by the first Medicare coverage of obesity drugs from mid-2026, which is expected to reach about one in ten beneficiaries.

By consumer demographic, the report covers adolescents and three adult groups: aged 18-44, aged 45-64, and aged 65 & above. Adults aged 45-64 are expected to account for the largest share in 2026, as obesity-related conditions such as diabetes and heart disease cluster in this age group, which raises both clinical eligibility and willingness to pay. Adults aged 65 and above are expected to grow at the highest CAGR, since Medicare coverage for people with a BMI above 27 and prediabetes or established heart disease opens a group that previously had no reimbursed access.

The distribution channel analysis includes retail & specialty pharmacies, hospital pharmacies, direct-to-patient & manufacturer channels, supermarkets & health stores, and online retail. Retail and specialty pharmacies are expected to lead in 2026, as they dispense most prescription obesity drugs under insurance benefits. Direct-to-patient and manufacturer channels are expected to grow at the highest CAGR, supported by manufacturer cash prices for injectables of about USD 350 a month, falling to USD 245 over two years under the U.S. agreements, and by the TrumpRx platform launched in January 2026.

Regional Analysis

The report covers North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, with analysis of 22 countries, the Nordic countries, Australia & New Zealand, Southeast Asia, and four rest-of-region groups. It considers obesity prevalence, launch timing, reimbursement, health system readiness, pricing, and patent expiry.

North America is expected to hold the largest share of the market in 2026, owing to high obesity rates, the earliest and widest use of incretin drugs, and the broadest insurance coverage. ASMBS data show GLP-1 prescriptions in a U.S. severe obesity cohort rising from 4,592 in 2018 to 1,421,202 in 2025. The November 2025 agreements extend Medicare coverage while sharply cutting direct prices, so the region combines the largest funded patient pool with the steepest price declines. Europe holds a significant share and is home to Novo Nordisk, though health technology assessment bodies have limited reimbursement of obesity drugs on cost grounds, which has slowed uptake compared with North America.

Asia-Pacific is expected to grow at the highest CAGR during the forecast period, as the World Obesity Federation projects the fastest rise in class II obesity and above in the Western Pacific and South-East Asia between 2010 and 2030, and as semaglutide patents lapse from 2026 in China, India, and other markets, local makers are expected to offer cheaper supply, while Japan, South Korea, and Australia are also widening access. The Middle East & Africa is expected to grow strongly, led by Gulf states with very high obesity rates and well-funded health systems, along with South Africa. Latin America should grow steadily, with Brazil and Mexico leading as generic semaglutide enters and established bariatric surgery sectors adapt.

Competitive Landscape

The report reviews key growth strategies, competitive benchmarking, the competitive dashboard, strategic developments (product approvals and launches, pricing and access agreements, capacity expansions, and partnerships, licensing, and acquisitions), and 2025 market share/rank analysis, with company profiles covering business overview, financials, product portfolio, developments, and SWOT analysis.

The market brings together two drug makers with dominant positions in incretin therapy, Novo Nordisk and Eli Lilly, a broad group of nutrition and supplement companies, device makers serving bariatric and endoscopic procedures, and fast-consolidating telehealth providers, while Boehringer Ingelheim, Amgen, Pfizer, AstraZeneca, and Roche are developing late-stage obesity drugs. Drug makers compete on efficacy, tolerability, route, supply, and price, and nutrition and service providers on brand, credibility, and reach. Leading companies are expanding peptide and oral manufacturing, advancing oral and multi-pathway agents, signing direct-to-patient and public payer pricing deals, and reformulating nutrition products for patients with reduced appetite.

Key companies profiled in the report include Novo Nordisk A/S (Denmark), Eli Lilly and Company (U.S.), Currax Pharmaceuticals LLC (U.S.), VIVUS LLC (U.S.), Boehringer Ingelheim International GmbH (Germany), Amgen Inc. (U.S.), Pfizer Inc. (U.S.), AstraZeneca PLC (U.K.), Roche Holding AG (Switzerland), Herbalife Ltd. (U.S.), Medifast, Inc. (U.S.), Nestlé S.A. (Switzerland), Abbott Laboratories (U.S.), Danone S.A. (France), Glanbia plc (Ireland), WW International, Inc. (U.S.), Hims & Hers Health, Inc. (U.S.), Noom, Inc. (U.S.), Medtronic plc (Ireland), Johnson & Johnson MedTech (U.S.), Apollo Endosurgery (Boston Scientific) (U.S.), and Allurion Technologies, Inc. (U.S.).

How This Report Helps

Provides reliable market size estimates and long-term forecasts for the global weight loss market through 2036.
Explains how obesity prevalence, incretin uptake, and new reimbursement are reshaping demand across drugs, nutrition, devices, and services.
Assesses the impact of price cuts, poor persistence, supply limits, and surgical substitution on market value.
Identifies high-growth opportunities across offering, drug class, route, intervention setting, payer, demographic, channel, and region.
Tracks the late-stage pipeline, including oral and multi-pathway agents, and the outlook for semaglutide generics.
Benchmarks leading drug makers, nutrition companies, device makers, and telehealth providers on products, access, and strategy.
Supports portfolio, pricing, access, and investment decisions for drug, nutrition, and device companies, payers, and investors.

Key Questions Answered

How large is the global weight loss market today, and how will it grow through 2036?
How will negotiated price cuts and new Medicare coverage change revenue per patient and treated volumes?
What are the main drivers, restraints, opportunities, challenges, and trends shaping the market?
How quickly will oral and multi-pathway incretin drugs take share from current injectables?
How is drug therapy affecting bariatric surgery and device demand?
Which offerings, drug classes, payers, settings, and channels will grow the fastest?
Which regions and countries offer the most attractive opportunities as semaglutide patents expire?
Who are the leading companies in the market, and how do they compare?
What pricing deals, capacity investments, and acquisitions are shaping competition?

1. Introduction

1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency and Limitations
1.3.1. Currency
1.3.2. Limitations
1.4. Scope of the Study
1.5. Key Stakeholders

2. Research Methodology

2.1. Research Approach
2.2. Data Collection & Validation Process
2.2.1. Secondary Research
2.2.2. Primary Research & Validation
2.2.2.1. Primary Interviews with Industry Experts
2.2.2.2. Country-Level Prevalence and Reimbursement Analysis
2.3. Market Estimation
2.3.1. Bottom-Up Approach (Treated Population x Annual Cost of Therapy)
2.3.2. Top-Down Approach (Company Reported Sales and Obesity-Indicated Share)
2.3.3. Forecast Methodology (Volume Expansion and Net Price Trajectory)
2.4. Data Triangulation
2.5. Assumptions

3. Executive Summary

3.1. Key Findings
3.2. Market Snapshot
3.3. Strategic Insights
3.4. Analyst Perspective

4. Market Insights

4.1. Industry Overview
4.2. Obesity Epidemiology and Disease Burden
4.2.1. Global and Regional Obesity Prevalence Trends
4.2.2. Class II Obesity and Above by Region
4.2.3. Childhood and Adolescent Obesity
4.2.4. Comorbidity and Mortality Burden Attributable to High BMI
4.2.5. Treated versus Untreated Population Analysis
4.3. Treatment Pathway Analysis
4.3.1. Lifestyle and Behavioural Intervention
4.3.2. Nutrition and Meal Replacement Intervention
4.3.3. Pharmacotherapy Initiation, Titration and Maintenance
4.3.4. Endoscopic and Device-Based Intervention
4.3.5. Metabolic and Bariatric Surgery
4.3.6. Substitution Dynamics between Pharmacotherapy and Surgery
4.4. Technology and Product Landscape
4.4.1. Incretin Mechanism Landscape (GLP-1, GIP, Glucagon, Amylin)
4.4.2. Oral Peptide and Small-Molecule Formulation Technologies
4.4.3. Muscle-Preservation and Body Composition Approaches
4.4.4. Delivery Devices and Autoinjectors
4.4.5. Digital Therapeutics, Apps and Remote Monitoring
4.4.6. Nutrition Formulation for Reduced Appetite
4.5. Clinical Pipeline Analysis
4.5.1. Late-Stage Obesity Pharmacotherapy Pipeline
4.5.2. Oral Agents in Development
4.5.3. Combination and Next-Generation Mechanisms
4.5.4. Cardiometabolic Outcome Trial Landscape
4.6. Pricing and Reimbursement Analysis
4.6.1. List Prices versus Negotiated Net Prices
4.6.2. U.S. Medicare and Medicaid Coverage Developments
4.6.3. Direct-to-Patient Pricing Channels
4.6.4. Commercial and Employer Plan Coverage
4.6.5. European Health Technology Assessment Positions
4.6.6. Emerging Market Pricing and Generic Entry
4.7. Patent Expiry and Generic/Biosimilar Outlook
4.8. Regulatory Landscape
4.8.1. Obesity Indication Approval Pathways
4.8.2. Compounded and Unapproved Product Enforcement
4.8.3. Dietary Supplement and Health Claim Regulation
4.8.4. Advertising and Direct-to-Consumer Promotion Rules
4.9. Health System Readiness and Policy Analysis
4.10. Value Chain Analysis
4.11. Supply Chain and Manufacturing Capacity Analysis
4.12. Patent Analysis
4.13. Investment, Partnership and M&A Landscape
4.14. Porter's Five Forces Analysis
4.15. Industry Attractiveness Assessment

5. Market Dynamics

5.1. Drivers
5.1.1. Rising Global Prevalence of Obesity and Overweight
5.1.2. Clinical Effectiveness and Rapid Uptake of Incretin Pharmacotherapy
5.1.3. Extension of Insurance and Public Reimbursement
5.1.4. Reclassification of Obesity as a Chronic Disease
5.1.5. Large Untreated Population
5.2. Restraints
5.2.1. Steep Price Reductions Negotiated by Payers and Governments
5.2.2. Poor Treatment Persistence and High Discontinuation
5.2.3. Supply and Manufacturing Constraints on Incretin Products
5.2.4. Displacement of Surgical and Device Procedures
5.3. Opportunities
5.3.1. Oral Small-Molecule Weight Loss Drugs
5.3.2. Public Payer Coverage of Obesity Treatment
5.3.3. Nutrition and Muscle-Preservation Products for Patients on Therapy
5.3.4. Expansion into Emerging Markets
5.4. Challenges
5.4.1. Limited Readiness of National Health Systems
5.4.2. Long-Term Safety and Muscle-Loss Concerns
5.4.3. Compounded and Counterfeit Product Proliferation
5.4.4. Weight Regain Following Discontinuation
5.5. Key Trends
5.5.1. Shift from Injectable to Oral Administration
5.5.2. Combination Therapies Targeting Multiple Incretin Pathways
5.5.3. Integration of Digital and Telehealth Delivery with Pharmacotherapy
5.5.4. Convergence of Weight Loss with Cardiometabolic Outcome Indications

6. Weight Loss Market, by Offering

6.1. Introduction
6.2. Weight Loss Pharmacotherapy
6.2.1. Branded Prescription Therapy
6.2.2. Generic and Biosimilar Therapy
6.3. Nutrition & Meal Replacement
6.3.1. Meal Replacement Shakes, Bars & Powders
6.3.2. Prepared Meal and Portion-Controlled Plans
6.3.3. Weight-Management Foods & Beverages
6.3.3.1. Low-Calorie and Reduced-Sugar Products
6.3.3.2. High-Protein and Satiety Products
6.3.3.3. High-Fibre and Gut Health Products
6.3.4. Dietary Supplements
6.3.4.1. Protein and Amino Acid Supplements
6.3.4.2. Fat Burners and Thermogenics
6.3.4.3. Appetite Suppressants and Fibre Supplements
6.3.4.4. Vitamins and Micronutrient Support
6.4. Devices & Surgical Products
6.4.1. Bariatric Surgical Devices
6.4.1.1. Surgical Staplers and Reloads
6.4.1.2. Energy and Sealing Devices
6.4.1.3. Gastric Bands
6.4.2. Endoscopic and Space-Occupying Devices
6.4.2.1. Intragastric Balloons
6.4.2.2. Endoscopic Suturing and Sleeve Systems
6.4.3. Gastric Electrical Stimulation Devices
6.4.4. Non-Invasive Body Contouring Devices
6.5. Services & Programs
6.5.1. Commercial Weight Loss Programs
6.5.2. Physician-Supervised and Clinical Nutrition Services
6.5.3. Digital and Telehealth Platforms
6.5.3.1. Prescription-Integrated Telehealth
6.5.3.2. Coaching and Behavioural Apps
6.5.4. Behavioural and Psychological Counselling

7. Weight Loss Market, by Drug Class

7.1. Introduction
7.2. GLP-1 Receptor Agonists
7.2.1. Semaglutide
7.2.2. Liraglutide
7.2.3. Other GLP-1 Agonists
7.3. Dual & Triple Incretin Agonists
7.3.1. GLP-1/GIP Dual Agonists
7.3.2. GLP-1/Glucagon and Triple Agonists
7.4. Amylin Analogues & Combinations
7.5. Conventional Anti-Obesity Agents
7.5.1. Phentermine and Combinations
7.5.2. Naltrexone-Bupropion
7.5.3. Orlistat

8. Weight Loss Market, by Route of Administration

8.1. Introduction
8.2. Injectable
8.2.1. Weekly Subcutaneous
8.2.2. Daily Subcutaneous
8.3. Oral
8.3.1. Oral Peptide
8.3.2. Oral Small Molecule

9. Weight Loss Market, by Intervention Setting

9.1. Introduction
9.2. Self-Directed & Retail
9.3. Primary Care
9.4. Specialty Obesity & Endocrinology Clinics
9.5. Hospitals & Surgical Centers
9.6. Digital & Telehealth

10. Weight Loss Market, by Payer

10.1. Introduction
10.2. Out-of-Pocket
10.3. Commercial Insurance
10.4. Public Insurance & Government Programs
10.4.1. Medicare
10.4.2. Medicaid
10.4.3. National Health Systems Outside the U.S.
10.5. Employer-Sponsored Plans

11. Weight Loss Market, by Consumer Demographic

11.1. Introduction
11.2. Adults Aged 18-44
11.3. Adults Aged 45-64
11.4. Adults Aged 65 & Above
11.5. Adolescents

12. Weight Loss Market, by Distribution Channel

12.1. Introduction
12.2. Retail & Specialty Pharmacies
12.3. Hospital Pharmacies
12.4. Direct-to-Patient & Manufacturer Channels
12.5. Supermarkets & Health Stores
12.6. Online Retail

13. Weight Loss Market, by Geography

13.1. Introduction
13.2. North America
13.2.1. U.S.
13.2.2. Canada
13.3. Europe
13.3.1. Germany
13.3.2. U.K.
13.3.3. France
13.3.4. Italy
13.3.5. Spain
13.3.6. Denmark
13.3.7. Nordic Countries
13.3.8. Rest of Europe
13.4. Asia-Pacific
13.4.1. China
13.4.2. Japan
13.4.3. India
13.4.4. South Korea
13.4.5. Australia & New Zealand
13.4.6. Southeast Asia
13.4.7. Rest of Asia-Pacific
13.5. Latin America
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Argentina
13.5.4. Colombia
13.5.5. Rest of Latin America
13.6. Middle East & Africa
13.6.1. Saudi Arabia
13.6.2. UAE
13.6.3. Kuwait
13.6.4. Qatar
13.6.5. Israel
13.6.6. South Africa
13.6.7. Rest of Middle East & Africa

14. Competitive Landscape

14.1. Overview
14.2. Key Growth Strategies
14.3. Competitive Benchmarking
14.4. Competitive Dashboard
14.4.1. Industry Leaders
14.4.2. Market Differentiators
14.4.3. Vanguards
14.4.4. Emerging Companies
14.5. Strategic Developments
14.5.1. Product Approvals and Launches
14.5.2. Pricing and Access Agreements
14.5.3. Capacity Expansions and Manufacturing Investments
14.5.4. Partnerships, Licensing and Acquisitions
14.6. Market Share/Rank Analysis, by Key Player (2025)

15. Company Profiles

(Business Overview, Financial Overview, Product Portfolio, Strategic Developments, SWOT Analysis)
Obesity Pharmacotherapy Companies with Marketed Products
15.1. Novo Nordisk A/S
15.2. Eli Lilly and Company
15.3. Currax Pharmaceuticals LLC
15.4. VIVUS LLC
Late-Stage Obesity Pipeline Developers
15.5. Boehringer Ingelheim International GmbH
15.6. Amgen Inc.
15.7. Pfizer Inc.
15.8. AstraZeneca PLC
15.9. Roche Holding AG
Nutrition and Meal Replacement Companies
15.10. Herbalife Ltd.
15.11. Medifast, Inc.
15.12. Nestlé S.A.
15.13. Abbott Laboratories
15.14. Danone S.A.
15.15. Glanbia plc
Services, Programs and Digital Platforms
15.16. WW International, Inc.
15.17. Hims & Hers Health, Inc.
15.18. Noom, Inc.
Devices and Surgical Product Manufacturers
15.19. Medtronic plc
15.20. Johnson & Johnson MedTech
15.21. Apollo Endosurgery (Boston Scientific)
15.22. Allurion Technologies, Inc.

16. Appendix

16.1. Related Reports
16.2. Customization Options

LIST OF TABLES

Table 1. Global Weight Loss Market Drivers: Impact Analysis (2026-2036)
Table 2. Global Weight Loss Market Restraints: Impact Analysis (2026-2036)
Table 3. Global Weight Loss Market Opportunities: Impact Analysis (2026-2036)
Table 4. Global Weight Loss Market Challenges: Impact Analysis (2026-2036)
Table 5. Global and Regional Adult Obesity Prevalence, 2010-2030
Table 6. Class II Obesity and Above, by WHO Region, 2010-2030
Table 7. Selected Late-Stage Obesity Pharmacotherapy Pipeline Candidates, by Mechanism
Table 8. U.S. Obesity Drug Pricing: List Prices versus Negotiated Medicare, Medicaid and Direct-to-Patient Prices
Table 9. European Health Technology Assessment Positions on Obesity Pharmacotherapy, by Country
Table 10. Semaglutide Patent Expiry and Generic/Biosimilar Entry Timeline, by Country
Table 11. Key Regulatory Pathways and Enforcement Actions Affecting the Weight Loss Market
Table 12. Porter's Five Forces Analysis: Weight Loss Market
Table 13. Global Weight Loss Market, by Offering, 2024-2036 (USD Million)
Table 14. Global Weight Loss Market for Weight Loss Pharmacotherapy, by Type, 2024-2036 (USD Million)
Table 15. Weight Loss Market for Weight Loss Pharmacotherapy, by Country/Region, 2024-2036 (USD Million)
Table 16. Weight Loss Market for Branded Prescription Therapy, by Country/Region, 2024-2036 (USD Million)
Table 17. Weight Loss Market for Generic and Biosimilar Therapy, by Country/Region, 2024-2036 (USD Million)
Table 18. Global Weight Loss Market for Nutrition & Meal Replacement, by Type, 2024-2036 (USD Million)
Table 19. Weight Loss Market for Nutrition & Meal Replacement, by Country/Region, 2024-2036 (USD Million)
Table 20. Weight Loss Market for Meal Replacement Shakes, Bars & Powders, by Country/Region, 2024-2036 (USD Million)
Table 21. Weight Loss Market for Prepared Meal and Portion-Controlled Plans, by Country/Region, 2024-2036 (USD Million)
Table 22. Weight Loss Market for Weight-Management Foods & Beverages, by Country/Region, 2024-2036 (USD Million)
Table 23. Weight Loss Market for Dietary Supplements, by Country/Region, 2024-2036 (USD Million)
Table 24. Global Weight Loss Market for Devices & Surgical Products, by Type, 2024-2036 (USD Million)
Table 25. Weight Loss Market for Devices & Surgical Products, by Country/Region, 2024-2036 (USD Million)
Table 26. Weight Loss Market for Bariatric Surgical Devices, by Country/Region, 2024-2036 (USD Million)
Table 27. Weight Loss Market for Endoscopic and Space-Occupying Devices, by Country/Region, 2024-2036 (USD Million)
Table 28. Weight Loss Market for Gastric Electrical Stimulation Devices, by Country/Region, 2024-2036 (USD Million)
Table 29. Weight Loss Market for Non-Invasive Body Contouring Devices, by Country/Region, 2024-2036 (USD Million)
Table 30. Global Weight Loss Market for Services & Programs, by Type, 2024-2036 (USD Million)
Table 31. Weight Loss Market for Services & Programs, by Country/Region, 2024-2036 (USD Million)
Table 32. Weight Loss Market for Commercial Weight Loss Programs, by Country/Region, 2024-2036 (USD Million)
Table 33. Weight Loss Market for Physician-Supervised and Clinical Nutrition Services, by Country/Region, 2024-2036 (USD Million)
Table 34. Weight Loss Market for Digital and Telehealth Platforms, by Country/Region, 2024-2036 (USD Million)
Table 35. Weight Loss Market for Behavioural and Psychological Counselling, by Country/Region, 2024-2036 (USD Million)
Table 36. Global Weight Loss Market, by Drug Class, 2024-2036 (USD Million)
Table 37. Global Weight Loss Market for GLP-1 Receptor Agonists, by Type, 2024-2036 (USD Million)
Table 38. Weight Loss Market for GLP-1 Receptor Agonists, by Country/Region, 2024-2036 (USD Million)
Table 39. Weight Loss Market for Semaglutide, by Country/Region, 2024-2036 (USD Million)
Table 40. Weight Loss Market for Liraglutide, by Country/Region, 2024-2036 (USD Million)
Table 41. Weight Loss Market for Other GLP-1 Agonists, by Country/Region, 2024-2036 (USD Million)
Table 42. Global Weight Loss Market for Dual & Triple Incretin Agonists, by Type, 2024-2036 (USD Million)
Table 43. Weight Loss Market for Dual & Triple Incretin Agonists, by Country/Region, 2024-2036 (USD Million)
Table 44. Weight Loss Market for GLP-1/GIP Dual Agonists, by Country/Region, 2024-2036 (USD Million)
Table 45. Weight Loss Market for GLP-1/Glucagon and Triple Agonists, by Country/Region, 2024-2036 (USD Million)
Table 46. Weight Loss Market for Amylin Analogues & Combinations, by Country/Region, 2024-2036 (USD Million)
Table 47. Global Weight Loss Market for Conventional Anti-Obesity Agents, by Type, 2024-2036 (USD Million)
Table 48. Weight Loss Market for Conventional Anti-Obesity Agents, by Country/Region, 2024-2036 (USD Million)
Table 49. Weight Loss Market for Phentermine and Combinations, by Country/Region, 2024-2036 (USD Million)
Table 50. Weight Loss Market for Naltrexone-Bupropion, by Country/Region, 2024-2036 (USD Million)
Table 51. Weight Loss Market for Orlistat, by Country/Region, 2024-2036 (USD Million)
Table 52. Global Weight Loss Market, by Route of Administration, 2024-2036 (USD Million)
Table 53. Global Weight Loss Market for Injectable, by Type, 2024-2036 (USD Million)
Table 54. Weight Loss Market for Injectable, by Country/Region, 2024-2036 (USD Million)
Table 55. Weight Loss Market for Weekly Subcutaneous, by Country/Region, 2024-2036 (USD Million)
Table 56. Weight Loss Market for Daily Subcutaneous, by Country/Region, 2024-2036 (USD Million)
Table 57. Global Weight Loss Market for Oral, by Type, 2024-2036 (USD Million)
Table 58. Weight Loss Market for Oral, by Country/Region, 2024-2036 (USD Million)
Table 59. Weight Loss Market for Oral Peptide, by Country/Region, 2024-2036 (USD Million)
Table 60. Weight Loss Market for Oral Small Molecule, by Country/Region, 2024-2036 (USD Million)
Table 61. Global Weight Loss Market, by Intervention Setting, 2024-2036 (USD Million)
Table 62. Weight Loss Market for Self-Directed & Retail, by Country/Region, 2024-2036 (USD Million)
Table 63. Weight Loss Market for Primary Care, by Country/Region, 2024-2036 (USD Million)
Table 64. Weight Loss Market for Specialty Obesity & Endocrinology Clinics, by Country/Region, 2024-2036 (USD Million)
Table 65. Weight Loss Market for Hospitals & Surgical Centers, by Country/Region, 2024-2036 (USD Million)
Table 66. Weight Loss Market for Digital & Telehealth, by Country/Region, 2024-2036 (USD Million)
Table 67. Global Weight Loss Market, by Payer, 2024-2036 (USD Million)
Table 68. Weight Loss Market for Out-of-Pocket, by Country/Region, 2024-2036 (USD Million)
Table 69. Weight Loss Market for Commercial Insurance, by Country/Region, 2024-2036 (USD Million)
Table 70. Global Weight Loss Market for Public Insurance & Government Programs, by Type, 2024-2036 (USD Million)
Table 71. Weight Loss Market for Public Insurance & Government Programs, by Country/Region, 2024-2036 (USD Million)
Table 72. Weight Loss Market for Medicare, by Country/Region, 2024-2036 (USD Million)
Table 73. Weight Loss Market for Medicaid, by Country/Region, 2024-2036 (USD Million)
Table 74. Weight Loss Market for National Health Systems Outside the U.S., by Country/Region, 2024-2036 (USD Million)
Table 75. Weight Loss Market for Employer-Sponsored Plans, by Country/Region, 2024-2036 (USD Million)
Table 76. Global Weight Loss Market, by Consumer Demographic, 2024-2036 (USD Million)
Table 77. Weight Loss Market for Adults Aged 18-44, by Country/Region, 2024-2036 (USD Million)
Table 78. Weight Loss Market for Adults Aged 45-64, by Country/Region, 2024-2036 (USD Million)
Table 79. Weight Loss Market for Adults Aged 65 & Above, by Country/Region, 2024-2036 (USD Million)
Table 80. Weight Loss Market for Adolescents, by Country/Region, 2024-2036 (USD Million)
Table 81. Global Weight Loss Market, by Distribution Channel, 2024-2036 (USD Million)
Table 82. Weight Loss Market for Retail & Specialty Pharmacies, by Country/Region, 2024-2036 (USD Million)
Table 83. Weight Loss Market for Hospital Pharmacies, by Country/Region, 2024-2036 (USD Million)
Table 84. Weight Loss Market for Direct-to-Patient & Manufacturer Channels, by Country/Region, 2024-2036 (USD Million)
Table 85. Weight Loss Market for Supermarkets & Health Stores, by Country/Region, 2024-2036 (USD Million)
Table 86. Weight Loss Market for Online Retail, by Country/Region, 2024-2036 (USD Million)
Table 87. Global Weight Loss Market, by Region, 2024-2036 (USD Million)
Table 88. Global Weight Loss Market, by Country/Region, 2024-2036 (USD Million)
Table 89. North America: Weight Loss Market, by Country, 2024-2036 (USD Million)
Table 90. North America: Weight Loss Market, by Offering, 2024-2036 (USD Million)
Table 91. North America: Weight Loss Market for Weight Loss Pharmacotherapy, by Type, 2024-2036 (USD Million)
Table 92. North America: Weight Loss Market for Nutrition & Meal Replacement, by Type, 2024-2036 (USD Million)
Table 93. North America: Weight Loss Market for Devices & Surgical Products, by Type, 2024-2036 (USD Million)
Table 94. North America: Weight Loss Market for Services & Programs, by Type, 2024-2036 (USD Million)
Table 95. North America: Weight Loss Market, by Drug Class, 2024-2036 (USD Million)
Table 96. North America: Weight Loss Market for GLP-1 Receptor Agonists, by Type, 2024-2036 (USD Million)
Table 97. North America: Weight Loss Market for Dual & Triple Incretin Agonists, by Type, 2024-2036 (USD Million)
Table 98. North America: Weight Loss Market for Conventional Anti-Obesity Agents, by Type, 2024-2036 (USD Million)
Table 99. North America: Weight Loss Market, by Route of Administration, 2024-2036 (USD Million)
Table 100. North America: Weight Loss Market for Injectable, by Type, 2024-2036 (USD Million)
Table 101. North America: Weight Loss Market for Oral, by Type, 2024-2036 (USD Million)
Table 102. North America: Weight Loss Market, by Intervention Setting, 2024-2036 (USD Million)
Table 103. North America: Weight Loss Market, by Payer, 2024-2036 (USD Million)
Table 104. North America: Weight Loss Market for Public Insurance & Government Programs, by Type, 2024-2036 (USD Million)
Table 105. North America: Weight Loss Market, by Consumer Demographic, 2024-2036 (USD Million)
Table 106. North America: Weight Loss Market, by Distribution Channel, 2024-2036 (USD Million)
Table 107. U.S.: Weight Loss Market, by Offering, 2024-2036 (USD Million)
Table 108. U.S.: Weight Loss Market for Weight Loss Pharmacotherapy, by Type, 2024-2036 (USD Million)
Table 109. U.S.: Weight Loss Market for Nutrition & Meal Replacement, by Type, 2024-2036 (USD Million)
Table 110. U.S.: Weight Loss Market for Devices & Surgical Products, by Type, 2024-2036 (USD Million)
Table 111. U.S.: Weight Loss Market for Services & Programs, by Type, 2024-2036 (USD Million)
Table 112. U.S.: Weight Loss Market, by Drug Class, 2024-2036 (USD Million)
Table 113. U.S.: Weight Loss Market for GLP-1 Receptor Agonists, by Type, 2024-2036 (USD Million)
Table 114. U.S.: Weight Loss Market for Dual & Triple Incretin Agonists, by Type, 2024-2036 (USD Million)
Table 115. U.S.: Weight Loss Market for Conventional Anti-Obesity Agents, by Type, 2024-2036 (USD Million)
Table 116. U.S.: Weight Loss Market, by Route of Administration, 2024-2036 (USD Million)
Table 117. U.S.: Weight Loss Market for Injectable, by Type, 2024-2036 (USD Million)
Table 118. U.S.: Weight Loss Market for Oral, by Type, 2024-2036 (USD Million)
Table 119. U.S.: Weight Loss Market, by Intervention Setting, 2024-2036 (USD Million)
Table 120. U.S.: Weight Loss Market, by Payer, 2024-2036 (USD Million)
Table 121. U.S.: Weight Loss Market for Public Insurance & Government Programs, by Type, 2024-2036 (USD Million)
Table 122. U.S.: Weight Loss Market, by Consumer Demographic, 2024-2036 (USD Million)
Table 123. U.S.: Weight Loss Market, by Distribution Channel, 2024-2036 (USD Million)
Table 124. Canada: Weight Loss Market, by Offering, 2024-2036 (USD Million)
Table 125. Canada: Weight Loss Market for Weight Loss Pharmacotherapy, by Type, 2024-2036 (USD Million)
Table 126. Canada: Weight Loss Market for Nutrition & Meal Replacement, by Type, 2024-2036 (USD Million)
Table 127. Canada: Weight Loss Market for Devices & Surgical Products, by Type, 2024-2036 (USD Million)
Table 128. Canada: Weight Loss Market for Services & Programs, by Type, 2024-2036 (USD Million)
Table 129. Canada: Weight Loss Market, by Drug Class, 2024-2036 (USD Million)
Table 130. Canada: Weight Loss Market for GLP-1 Receptor Agonists, by Type, 2024-2036 (USD Million)
Table 131. Canada: Weight Loss Market for Dual & Triple Incretin Agonists, by Type, 2024-2036 (USD Million)
Table 132. Canada: Weight Loss Market for Conventional Anti-Obesity Agents, by Type, 2024-2036 (USD Million)
Table 133. Canada: Weight Loss Market, by Route of Administration, 2024-2036 (USD Million)
Table 134. Canada: Weight Loss Market for Injectable, by Type, 2024-2036 (USD Million)
Table 135. Canada: Weight Loss Market for Oral, by Type, 2024-2036 (USD Million)
Table 136. Canada: Weight Loss Market, by Intervention Setting, 2024-2036 (USD Million)
Table 137. Canada: Weight Loss Market, by Payer, 2024-2036 (USD Million)
Table 138. Canada: Weight Loss Market for Public Insurance & Government Programs, by Type, 2024-2036 (USD Million)
Table 139. Canada: Weight Loss Market, by Consumer Demographic, 2024-2036 (USD Million)
Table 140. Canada: Weight Loss Market, by Distribution Channel, 2024-2036 (USD Million)
Table 141. Europe: Weight Loss Market, by Country, 2024-2036 (USD Million)
Table 142. Europe: Weight Loss Market, by Offering, 2024-2036 (USD Million)
Table 143. Europe: Weight Loss Market for Weight Loss Pharmacotherapy, by Type, 2024-2036 (USD Million)
Table 144. Europe: Weight Loss Market for Nutrition & Meal Replacement, by Type, 2024-2036 (USD Million)
Table 145. Europe: Weight Loss Market for Devices & Surgical Products, by Type, 2024-2036 (USD Million)
Table 146. Europe: Weight Loss Market for Services & Programs, by Type, 2024-2036 (USD Million)
Table 147. Europe: Weight Loss Market, by Drug Class, 2024-2036 (USD Million)
Table 148. Europe: Weight Loss Market for GLP-1 Receptor Agonists, by Type, 2024-2036 (USD Million)
Table 149. Europe: Weight Loss Market for Dual & Triple Incretin Agonists, by Type, 2024-2036 (USD Million)
Table 150. Europe: Weight Loss Market for Conventional Anti-Obesity Agents, by Type, 2024-2036 (USD Million)
Table 151. Europe: Weight Loss Market, by Route of Administration, 2024-2036 (USD Million)
Table 152. Europe: Weight Loss Market for Injectable, by Type, 2024-2036 (USD Million)
Table 153. Europe: Weight Loss Market for Oral, by Type, 2024-2036 (USD Million)
Table 154. Europe: Weight Loss Market, by Intervention Setting, 2024-2036 (USD Million)
Table 155. Europe: Weight Loss Market, by Payer, 2024-2036 (USD Million)
Table 156. Europe: Weight Loss Market for Public Insurance & Government Programs, by Type, 2024-2036 (USD Million)
Table 157. Europe: Weight Loss Market, by Consumer Demographic, 2024-2036 (USD Million)
Table 158. Europe: Weight Loss Market, by Distribution Channel, 2024-2036 (USD Million)
Table 159. Germany: Weight Loss Market, by Offering, 2024-2036 (USD Million)
Table 160. Germany: Weight Loss Market for Weight Loss Pharmacotherapy, by Type, 2024-2036 (USD Million)
Table 161. Germany: Weight Loss Market for Nutrition & Meal Replacement, by Type, 2024-2036 (USD Million)
Table 162. Germany: Weight Loss Market for Devices & Surgical Products, by Type, 2024-2036 (USD Million)
Table 163. Germany: Weight Loss Market for Services & Programs, by Type, 2024-2036 (USD Million)
Table 164. Germany: Weight Loss Market, by Drug Class, 2024-2036 (USD Million)
Table 165. Germany: Weight Loss Market for GLP-1 Receptor Agonists, by Type, 2024-2036 (USD Million)
Table 166. Germany: Weight Loss Market for Dual & Triple Incretin Agonists, by Type, 2024-2036 (USD Million)
Table 167. Germany: Weight Loss Market for Conventional Anti-Obesity Agents, by Type, 2024-2036 (USD Million)
Table 168. Germany: Weight Loss Market, by Route of Administration, 2024-2036 (USD Million)
Table 169. Germany: Weight Loss Market for Injectable, by Type, 2024-2036 (USD Million)
Table 170. Germany: Weight Loss Market for Oral, by Type, 2024-2036 (USD Million)
Table 171. Germany: Weight Loss Market, by Intervention Setting, 2024-2036 (USD Million)
Table 172. Germany: Weight Loss Market, by Payer, 2024-2036 (USD Million)
Table 173. Germany: Weight Loss Market for Public Insurance & Government Programs, by Type, 2024-2036 (USD Million)
Table 174. Germany: Weight Loss Market, by Consumer Demographic, 2024-2036 (USD Million)
Table 175. Germany: Weight Loss Market, by Distribution Channel, 2024-2036 (USD Million)
Table 176. U.K.: Weight Loss Market, by Offering, 2024-2036 (USD Million)
Table 177. U.K.: Weight Loss Market for Weight Loss Pharmacotherapy, by Type, 2024-2036 (USD Million)
Table 178. U.K.: Weight Loss Market for Nutrition & Meal Replacement, by Type, 2024-2036 (USD Million)
Table 179. U.K.: Weight Loss Market for Devices & Surgical Products, by Type, 2024-2036 (USD Million)
Table 180. U.K.: Weight Loss Market for Services & Programs, by Type, 2024-2036 (USD Million)
Table 181. U.K.: Weight Loss Market, by Drug Class, 2024-2036 (USD Million)
Table 182. U.K.: Weight Loss Market for GLP-1 Receptor Agonists, by Type, 2024-2036 (USD Million)
Table 183. U.K.: Weight Loss Market for Dual & Triple Incretin Agonists, by Type, 2024-2036 (USD Million)
Table 184. U.K.: Weight Loss Market for Conventional Anti-Obesity Agents, by Type, 2024-2036 (USD Million)
Table 185. U.K.: Weight Loss Market, by Route of Administration, 2024-2036 (USD Million)
Table 186. U.K.: Weight Loss Market for Injectable, by Type, 2024-2036 (USD Million)
Table 187. U.K.: Weight Loss Market for Oral, by Type, 2024-2036 (USD Million)
Table 188. U.K.: Weight Loss Market, by Intervention Setting, 2024-2036 (USD Million)
Table 189. U.K.: Weight Loss Market, by Payer, 2024-2036 (USD Million)
Table 190. U.K.: Weight Loss Market for Public Insurance & Government Programs, by Type, 2024-2036 (USD Million)
Table 191. U.K.: Weight Loss Market, by Consumer Demographic, 2024-2036 (USD Million)
Table 192. U.K.: Weight Loss Market, by Distribution Channel, 2024-2036 (USD Million)
Table 193. France: Weight Loss Market, by Offering, 2024-2036 (USD Million)
Table 194. France: Weight Loss Market for Weight Loss Pharmacotherapy, by Type, 2024-2036 (USD Million)
Table 195. France: Weight Loss Market for Nutrition & Meal Replacement, by Type, 2024-2036 (USD Million)
Table 196. France: Weight Loss Market for Devices & Surgical Products, by Type, 2024-2036 (USD Million)
Table 197. France: Weight Loss Market for Services & Programs, by Type, 2024-2036 (USD Million)
Table 198. France: Weight Loss Market, by Drug Class, 2024-2036 (USD Million)
Table 199. France: Weight Loss Market for GLP-1 Receptor Agonists, by Type, 2024-2036 (USD Million)
Table 200. France: Weight Loss Market for Dual & Triple Incretin Agonists, by Type, 2024-2036 (USD Million)
Table 201. France: Weight Loss Market for Conventional Anti-Obesity Agents, by Type, 2024-2036 (USD Million)
Table 202. France: Weight Loss Market, by Route of Administration, 2024-2036 (USD Million)
Table 203. France: Weight Loss Market for Injectable, by Type, 2024-2036 (USD Million)
Table 204. France: Weight Loss Market for Oral, by Type, 2024-2036 (USD Million)
Table 205. France: Weight Loss Market, by Intervention Setting, 2024-2036 (USD Million)
Table 206. France: Weight Loss Market, by Payer, 2024-2036 (USD Million)
Table 207. France: Weight Loss Market for Public Insurance & Government Programs, by Type, 2024-2036 (USD Million)
Table 208. France: Weight Loss Market, by Consumer Demographic, 2024-2036 (USD Million)
Table 209. France: Weight Loss Market, by Distribution Channel, 2024-2036 (USD Million)
Table 210. Italy: Weight Loss Market, by Offering, 2024-2036 (USD Million)
Table 211. Italy: Weight Loss Market for Weight Loss Pharmacotherapy, by Type, 2024-2036 (USD Million)
Table 212. Italy: Weight Loss Market for Nutrition & Meal Replacement, by Type, 2024-2036 (USD Million)
Table 213. Italy: Weight Loss Market for Devices & Surgical Products, by Type, 2024-2036 (USD Million)
Table 214. Italy: Weight Loss Market for Services & Programs, by Type, 2024-2036 (USD Million)
Table 215. Italy: Weight Loss Market, by Drug Class, 2024-2036 (USD Million)
Table 216. Italy: Weight Loss Market for GLP-1 Receptor Agonists, by Type, 2024-2036 (USD Million)
Table 217. Italy: Weight Loss Market for Dual & Triple Incretin Agonists, by Type, 2024-2036 (USD Million)
Table 218. Italy: Weight Loss Market for Conventional Anti-Obesity Agents, by Type, 2024-2036 (USD Million)
Table 219. Italy: Weight Loss Market, by Route of Administration, 2024-2036 (USD Million)
Table 220. Italy: Weight Loss Market for Injectable, by Type, 2024-2036 (USD Million)
Table 221. Italy: Weight Loss Market for Oral, by Type, 2024-2036 (USD Million)
Table 222. Italy: Weight Loss Market, by Intervention Setting, 2024-2036 (USD Million)
Table 223. Italy: Weight Loss Market, by Payer, 2024-2036 (USD Million)
Table 224. Italy: Weight Loss Market for Public Insurance & Government Programs, by Type, 2024-2036 (USD Million)
Table 225. Italy: Weight Loss Market, by Consumer Demographic, 2024-2036 (USD Million)
Table 226. Italy: Weight Loss Market, by Distribution Channel, 2024-2036 (USD Million)
Table 227. Spain: Weight Loss Market, by Offering, 2024-2036 (USD Million)
Table 228. Spain: Weight Loss Market for Weight Loss Pharmacotherapy, by Type, 2024-2036 (USD Million)
Table 229. Spain: Weight Loss Market for Nutrition & Meal Replacement, by Type, 2024-2036 (USD Million)
Table 230. Spain: Weight Loss Market for Devices & Surgical Products, by Type, 2024-2036 (USD Million)
Table 231. Spain: Weight Loss Market for Services & Programs, by Type, 2024-2036 (USD Million)
Table 232. Spain: Weight Loss Market, by Drug Class, 2024-2036 (USD Million)
Table 233. Spain: Weight Loss Market for GLP-1 Receptor Agonists, by Type, 2024-2036 (USD Million)
Table 234. Spain: Weight Loss Market for Dual & Triple Incretin Agonists, by Type, 2024-2036 (USD Million)
Table 235. Spain: Weight Loss Market for Conventional Anti-Obesity Agents, by Type, 2024-2036 (USD Million)
Table 236. Spain: Weight Loss Market, by Route of Administration, 2024-2036 (USD Million)
Table 237. Spain: Weight Loss Market for Injectable, by Type, 2024-2036 (USD Million)
Table 238. Spain: Weight Loss Market for Oral, by Type, 2024-2036 (USD Million)
Table 239. Spain: Weight Loss Market, by Intervention Setting, 2024-2036 (USD Million)
Table 240. Spain: Weight Loss Market, by Payer, 2024-2036 (USD Million)
Table 241. Spain: Weight Loss Market for Public Insurance & Government Programs, by Type, 2024-2036 (USD Million)
Table 242. Spain: Weight Loss Market, by Consumer Demographic, 2024-2036 (USD Million)
Table 243. Spain: Weight Loss Market, by Distribution Channel, 2024-2036 (USD Million)
Table 244. Denmark: Weight Loss Market, by Offering, 2024-2036 (USD Million)
Table 245. Denmark: Weight Loss Market for Weight Loss Pharmacotherapy, by Type, 2024-2036 (USD Million)
Table 246. Denmark: Weight Loss Market for Nutrition & Meal Replacement, by Type, 2024-2036 (USD Million)
Table 247. Denmark: Weight Loss Market for Devices & Surgical Products, by Type, 2024-2036 (USD Million)
Table 248. Denmark: Weight Loss Market for Services & Programs, by Type, 2024-2036 (USD Million)
Table 249. Denmark: Weight Loss Market, by Drug Class, 2024-2036 (USD Million)
Table 250. Denmark: Weight Loss Market for GLP-1 Receptor Agonists, by Type, 2024-2036 (USD Million)
Table 251. Denmark: Weight Loss Market for Dual & Triple Incretin Agonists, by Type, 2024-2036 (USD Million)
Table 252. Denmark: Weight Loss Market for Conventional Anti-Obesity Agents, by Type, 2024-2036 (USD Million)
Table 253. Denmark: Weight Loss Market, by Route of Administration, 2024-2036 (USD Million)
Table 254. Denmark: Weight Loss Market for Injectable, by Type, 2024-2036 (USD Million)
Table 255. Denmark: Weight Loss Market for Oral, by Type, 2024-2036 (USD Million)
Table 256. Denmark: Weight Loss Market, by Intervention Setting, 2024-2036 (USD Million)
Table 257. Denmark: Weight Loss Market, by Payer, 2024-2036 (USD Million)
Table 258. Denmark: Weight Loss Market for Public Insurance & Government Programs, by Type, 2024-2036 (USD Million)
Table 259. Denmark: Weight Loss Market, by Consumer Demographic, 2024-2036 (USD Million)
Table 260. Denmark: Weight Loss Market, by Distribution Channel, 2024-2036 (USD Million)
Table 261. Nordic Countries: Weight Loss Market, by Offering, 2024-2036 (USD Million)
Table 262. Nordic Countries: Weight Loss Market for Weight Loss Pharmacotherapy, by Type, 2024-2036 (USD Million)
Table 263. Nordic Countries: Weight Loss Market for Nutrition & Meal Replacement, by Type, 2024-2036 (USD Million)
Table 264. Nordic Countries: Weight Loss Market for Devices & Surgical Products, by Type, 2024-2036 (USD Million)
Table 265. Nordic Countries: Weight Loss Market for Services & Programs, by Type, 2024-2036 (USD Million)
Table 266. Nordic Countries: Weight Loss Market, by Drug Class, 2024-2036 (USD Million)
Table 267. Nordic Countries: Weight Loss Market for GLP-1 Receptor Agonists, by Type, 2024-2036 (USD Million)
Table 268. Nordic Countries: Weight Loss Market for Dual & Triple Incretin Agonists, by Type, 2024-2036 (USD Million)
Table 269. Nordic Countries: Weight Loss Market for Conventional Anti-Obesity Agents, by Type, 2024-2036 (USD Million)
Table 270. Nordic Countries: Weight Loss Market, by Route of Administration, 2024-2036 (USD Million)
Table 271. Nordic Countries: Weight Loss Market for Injectable, by Type, 2024-2036 (USD Million)
Table 272. Nordic Countries: Weight Loss Market for Oral, by Type, 2024-2036 (USD Million)
Table 273. Nordic Countries: Weight Loss Market, by Intervention Setting, 2024-2036 (USD Million)
Table 274. Nordic Countries: Weight Loss Market, by Payer, 2024-2036 (USD Million)
Table 275. Nordic Countries: Weight Loss Market for Public Insurance & Government Programs, by Type, 2024-2036 (USD Million)
Table 276. Nordic Countries: Weight Loss Market, by Consumer Demographic, 2024-2036 (USD Million)
Table 277. Nordic Countries: Weight Loss Market, by Distribution Channel, 2024-2036 (USD Million)
Table 278. Rest of Europe: Weight Loss Market, by Offering, 2024-2036 (USD Million)
Table 279. Rest of Europe: Weight Loss Market for Weight Loss Pharmacotherapy, by Type, 2024-2036 (USD Million)
Table 280. Rest of Europe: Weight Loss Market for Nutrition & Meal Replacement, by Type, 2024-2036 (USD Million)
Table 281. Rest of Europe: Weight Loss Market for Devices & Surgical Products, by Type, 2024-2036 (USD Million)
Table 282. Rest of Europe: Weight Loss Market for Services & Programs, by Type, 2024-2036 (USD Million)
Table 283. Rest of Europe: Weight Loss Market, by Drug Class, 2024-2036 (USD Million)
Table 284. Rest of Europe: Weight Loss Market for GLP-1 Receptor Agonists, by Type, 2024-2036 (USD Million)
Table 285. Rest of Europe: Weight Loss Market for Dual & Triple Incretin Agonists, by Type, 2024-2036 (USD Million)
Table 286. Rest of Europe: Weight Loss Market for Conventional Anti-Obesity Agents, by Type, 2024-2036 (USD Million)
Table 287. Rest of Europe: Weight Loss Market, by Route of Administration, 2024-2036 (USD Million)
Table 288. Rest of Europe: Weight Loss Market for Injectable, by Type, 2024-2036 (USD Million)
Table 289. Rest of Europe: Weight Loss Market for Oral, by Type, 2024-2036 (USD Million)
Table 290. Rest of Europe: Weight Loss Market, by Intervention Setting, 2024-2036 (USD Million)
Table 291. Rest of Europe: Weight Loss Market, by Payer, 2024-2036 (USD Million)
Table 292. Rest of Europe: Weight Loss Market for Public Insurance & Government Programs, by Type, 2024-2036 (USD Million)
Table 293. Rest of Europe: Weight Loss Market, by Consumer Demographic, 2024-2036 (USD Million)
Table 294. Rest of Europe: Weight Loss Market, by Distribution Channel, 2024-2036 (USD Million)
Table 295. Asia-Pacific: Weight Loss Market, by Country, 2024-2036 (USD Million)
Table 296. Asia-Pacific: Weight Loss Market, by Offering, 2024-2036 (USD Million)
Table 297. Asia-Pacific: Weight Loss Market for Weight Loss Pharmacotherapy, by Type, 2024-2036 (USD Million)
Table 298. Asia-Pacific: Weight Loss Market for Nutrition & Meal Replacement, by Type, 2024-2036 (USD Million)
Table 299. Asia-Pacific: Weight Loss Market for Devices & Surgical Products, by Type, 2024-2036 (USD Million)
Table 300. Asia-Pacific: Weight Loss Market for Services & Programs, by Type, 2024-2036 (USD Million)
Table 301. Asia-Pacific: Weight Loss Market, by Drug Class, 2024-2036 (USD Million)
Table 302. Asia-Pacific: Weight Loss Market for GLP-1 Receptor Agonists, by Type, 2024-2036 (USD Million)
Table 303. Asia-Pacific: Weight Loss Market for Dual & Triple Incretin Agonists, by Type, 2024-2036 (USD Million)
Table 304. Asia-Pacific: Weight Loss Market for Conventional Anti-Obesity Agents, by Type, 2024-2036 (USD Million)
Table 305. Asia-Pacific: Weight Loss Market, by Route of Administration, 2024-2036 (USD Million)
Table 306. Asia-Pacific: Weight Loss Market for Injectable, by Type, 2024-2036 (USD Million)
Table 307. Asia-Pacific: Weight Loss Market for Oral, by Type, 2024-2036 (USD Million)
Table 308. Asia-Pacific: Weight Loss Market, by Intervention Setting, 2024-2036 (USD Million)
Table 309. Asia-Pacific: Weight Loss Market, by Payer, 2024-2036 (USD Million)
Table 310. Asia-Pacific: Weight Loss Market for Public Insurance & Government Programs, by Type, 2024-2036 (USD Million)
Table 311. Asia-Pacific: Weight Loss Market, by Consumer Demographic, 2024-2036 (USD Million)
Table 312. Asia-Pacific: Weight Loss Market, by Distribution Channel, 2024-2036 (USD Million)
Table 313. China: Weight Loss Market, by Offering, 2024-2036 (USD Million)
Table 314. China: Weight Loss Market for Weight Loss Pharmacotherapy, by Type, 2024-2036 (USD Million)
Table 315. China: Weight Loss Market for Nutrition & Meal Replacement, by Type, 2024-2036 (USD Million)
Table 316. China: Weight Loss Market for Devices & Surgical Products, by Type, 2024-2036 (USD Million)
Table 317. China: Weight Loss Market for Services & Programs, by Type, 2024-2036 (USD Million)
Table 318. China: Weight Loss Market, by Drug Class, 2024-2036 (USD Million)
Table 319. China: Weight Loss Market for GLP-1 Receptor Agonists, by Type, 2024-2036 (USD Million)
Table 320. China: Weight Loss Market for Dual & Triple Incretin Agonists, by Type, 2024-2036 (USD Million)
Table 321. China: Weight Loss Market for Conventional Anti-Obesity Agents, by Type, 2024-2036 (USD Million)
Table 322. China: Weight Loss Market, by Route of Administration, 2024-2036 (USD Million)
Table 323. China: Weight Loss Market for Injectable, by Type, 2024-2036 (USD Million)
Table 324. China: Weight Loss Market for Oral, by Type, 2024-2036 (USD Million)
Table 325. China: Weight Loss Market, by Intervention Setting, 2024-2036 (USD Million)
Table 326. China: Weight Loss Market, by Payer, 2024-2036 (USD Million)
Table 327. China: Weight Loss Market for Public Insurance & Government Programs, by Type, 2024-2036 (USD Million)
Table 328. China: Weight Loss Market, by Consumer Demographic, 2024-2036 (USD Million)
Table 329. China: Weight Loss Market, by Distribution Channel, 2024-2036 (USD Million)
Table 330. Japan: Weight Loss Market, by Offering, 2024-2036 (USD Million)
Table 331. Japan: Weight Loss Market for Weight Loss Pharmacotherapy, by Type, 2024-2036 (USD Million)
Table 332. Japan: Weight Loss Market for Nutrition & Meal Replacement, by Type, 2024-2036 (USD Million)
Table 333. Japan: Weight Loss Market for Devices & Surgical Products, by Type, 2024-2036 (USD Million)
Table 334. Japan: Weight Loss Market for Services & Programs, by Type, 2024-2036 (USD Million)
Table 335. Japan: Weight Loss Market, by Drug Class, 2024-2036 (USD Million)
Table 336. Japan: Weight Loss Market for GLP-1 Receptor Agonists, by Type, 2024-2036 (USD Million)
Table 337. Japan: Weight Loss Market for Dual & Triple Incretin Agonists, by Type, 2024-2036 (USD Million)
Table 338. Japan: Weight Loss Market for Conventional Anti-Obesity Agents, by Type, 2024-2036 (USD Million)
Table 339. Japan: Weight Loss Market, by Route of Administration, 2024-2036 (USD Million)
Table 340. Japan: Weight Loss Market for Injectable, by Type, 2024-2036 (USD Million)
Table 341. Japan: Weight Loss Market for Oral, by Type, 2024-2036 (USD Million)
Table 342. Japan: Weight Loss Market, by Intervention Setting, 2024-2036 (USD Million)
Table 343. Japan: Weight Loss Market, by Payer, 2024-2036 (USD Million)
Table 344. Japan: Weight Loss Market for Public Insurance & Government Programs, by Type, 2024-2036 (USD Million)
Table 345. Japan: Weight Loss Market, by Consumer Demographic, 2024-2036 (USD Million)
Table 346. Japan: Weight Loss Market, by Distribution Channel, 2024-2036 (USD Million)
Table 347. India: Weight Loss Market, by Offering, 2024-2036 (USD Million)
Table 348. India: Weight Loss Market for Weight Loss Pharmacotherapy, by Type, 2024-2036 (USD Million)
Table 349. India: Weight Loss Market for Nutrition & Meal Replacement, by Type, 2024-2036 (USD Million)
Table 350. India: Weight Loss Market for Devices & Surgical Products, by Type, 2024-2036 (USD Million)
Table 351. India: Weight Loss Market for Services & Programs, by Type, 2024-2036 (USD Million)
Table 352. India: Weight Loss Market, by Drug Class, 2024-2036 (USD Million)
Table 353. India: Weight Loss Market for GLP-1 Receptor Agonists, by Type, 2024-2036 (USD Million)
Table 354. India: Weight Loss Market for Dual & Triple Incretin Agonists, by Type, 2024-2036 (USD Million)
Table 355. India: Weight Loss Market for Conventional Anti-Obesity Agents, by Type, 2024-2036 (USD Million)
Table 356. India: Weight Loss Market, by Route of Administration, 2024-2036 (USD Million)
Table 357. India: Weight Loss Market for Injectable, by Type, 2024-2036 (USD Million)
Table 358. India: Weight Loss Market for Oral, by Type, 2024-2036 (USD Million)
Table 359. India: Weight Loss Market, by Intervention Setting, 2024-2036 (USD Million)
Table 360. India: Weight Loss Market, by Payer, 2024-2036 (USD Million)
Table 361. India: Weight Loss Market for Public Insurance & Government Programs, by Type, 2024-2036 (USD Million)
Table 362. India: Weight Loss Market, by Consumer Demographic, 2024-2036 (USD Million)
Table 363. India: Weight Loss Market, by Distribution Channel, 2024-2036 (USD Million)
Table 364. South Korea: Weight Loss Market, by Offering, 2024-2036 (USD Million)
Table 365. South Korea: Weight Loss Market for Weight Loss Pharmacotherapy, by Type, 2024-2036 (USD Million)
Table 366. South Korea: Weight Loss Market for Nutrition & Meal Replacement, by Type, 2024-2036 (USD Million)
Table 367. South Korea: Weight Loss Market for Devices & Surgical Products, by Type, 2024-2036 (USD Million)
Table 368. South Korea: Weight Loss Market for Services & Programs, by Type, 2024-2036 (USD Million)
Table 369. South Korea: Weight Loss Market, by Drug Class, 2024-2036 (USD Million)
Table 370. South Korea: Weight Loss Market for GLP-1 Receptor Agonists, by Type, 2024-2036 (USD Million)
Table 371. South Korea: Weight Loss Market for Dual & Triple Incretin Agonists, by Type, 2024-2036 (USD Million)
Table 372. South Korea: Weight Loss Market for Conventional Anti-Obesity Agents, by Type, 2024-2036 (USD Million)
Table 373. South Korea: Weight Loss Market, by Route of Administration, 2024-2036 (USD Million)
Table 374. South Korea: Weight Loss Market for Injectable, by Type, 2024-2036 (USD Million)
Table 375. South Korea: Weight Loss Market for Oral, by Type, 2024-2036 (USD Million)
Table 376. South Korea: Weight Loss Market, by Intervention Setting, 2024-2036 (USD Million)
Table 377. South Korea: Weight Loss Market, by Payer, 2024-2036 (USD Million)
Table 378. South Korea: Weight Loss Market for Public Insurance & Government Programs, by Type, 2024-2036 (USD Million)
Table 379. South Korea: Weight Loss Market, by Consumer Demographic, 2024-2036 (USD Million)
Table 380. South Korea: Weight Loss Market, by Distribution Channel, 2024-2036 (USD Million)
Table 381. Australia & New Zealand: Weight Loss Market, by Offering, 2024-2036 (USD Million)
Table 382. Australia & New Zealand: Weight Loss Market for Weight Loss Pharmacotherapy, by Type, 2024-2036 (USD Million)
Table 383. Australia & New Zealand: Weight Loss Market for Nutrition & Meal Replacement, by Type, 2024-2036 (USD Million)
Table 384. Australia & New Zealand: Weight Loss Market for Devices & Surgical Products, by Type, 2024-2036 (USD Million)
Table 385. Australia & New Zealand: Weight Loss Market for Services & Programs, by Type, 2024-2036 (USD Million)
Table 386. Australia & New Zealand: Weight Loss Market, by Drug Class, 2024-2036 (USD Million)
Table 387. Australia & New Zealand: Weight Loss Market for GLP-1 Receptor Agonists, by Type, 2024-2036 (USD Million)
Table 388. Australia & New Zealand: Weight Loss Market for Dual & Triple Incretin Agonists, by Type, 2024-2036 (USD Million)
Table 389. Australia & New Zealand: Weight Loss Market for Conventional Anti-Obesity Agents, by Type, 2024-2036 (USD Million)
Table 390. Australia & New Zealand: Weight Loss Market, by Route of Administration, 2024-2036 (USD Million)
Table 391. Australia & New Zealand: Weight Loss Market for Injectable, by Type, 2024-2036 (USD Million)
Table 392. Australia & New Zealand: Weight Loss Market for Oral, by Type, 2024-2036 (USD Million)
Table 393. Australia & New Zealand: Weight Loss Market, by Intervention Setting, 2024-2036 (USD Million)
Table 394. Australia & New Zealand: Weight Loss Market, by Payer, 2024-2036 (USD Million)
Table 395. Australia & New Zealand: Weight Loss Market for Public Insurance & Government Programs, by Type, 2024-2036 (USD Million)
Table 396. Australia & New Zealand: Weight Loss Market, by Consumer Demographic, 2024-2036 (USD Million)
Table 397. Australia & New Zealand: Weight Loss Market, by Distribution Channel, 2024-2036 (USD Million)
Table 398. Southeast Asia: Weight Loss Market, by Offering, 2024-2036 (USD Million)
Table 399. Southeast Asia: Weight Loss Market for Weight Loss Pharmacotherapy, by Type, 2024-2036 (USD Million)
Table 400. Southeast Asia: Weight Loss Market for Nutrition & Meal Replacement, by Type, 2024-2036 (USD Million)
Table 401. Southeast Asia: Weight Loss Market for Devices & Surgical Products, by Type, 2024-2036 (USD Million)
Table 402. Southeast Asia: Weight Loss Market for Services & Programs, by Type, 2024-2036 (USD Million)
Table 403. Southeast Asia: Weight Loss Market, by Drug Class, 2024-2036 (USD Million)
Table 404. Southeast Asia: Weight Loss Market for GLP-1 Receptor Agonists, by Type, 2024-2036 (USD Million)
Table 405. Southeast Asia: Weight Loss Market for Dual & Triple Incretin Agonists, by Type, 2024-2036 (USD Million)
Table 406. Southeast Asia: Weight Loss Market for Conventional Anti-Obesity Agents, by Type, 2024-2036 (USD Million)
Table 407. Southeast Asia: Weight Loss Market, by Route of Administration, 2024-2036 (USD Million)
Table 408. Southeast Asia: Weight Loss Market for Injectable, by Type, 2024-2036 (USD Million)
Table 409. Southeast Asia: Weight Loss Market for Oral, by Type, 2024-2036 (USD Million)
Table 410. Southeast Asia: Weight Loss Market, by Intervention Setting, 2024-2036 (USD Million)
Table 411. Southeast Asia: Weight Loss Market, by Payer, 2024-2036 (USD Million)
Table 412. Southeast Asia: Weight Loss Market for Public Insurance & Government Programs, by Type, 2024-2036 (USD Million)
Table 413. Southeast Asia: Weight Loss Market, by Consumer Demographic, 2024-2036 (USD Million)
Table 414. Southeast Asia: Weight Loss Market, by Distribution Channel, 2024-2036 (USD Million)
Table 415. Rest of Asia-Pacific: Weight Loss Market, by Offering, 2024-2036 (USD Million)
Table 416. Rest of Asia-Pacific: Weight Loss Market for Weight Loss Pharmacotherapy, by Type, 2024-2036 (USD Million)
Table 417. Rest of Asia-Pacific: Weight Loss Market for Nutrition & Meal Replacement, by Type, 2024-2036 (USD Million)
Table 418. Rest of Asia-Pacific: Weight Loss Market for Devices & Surgical Products, by Type, 2024-2036 (USD Million)
Table 419. Rest of Asia-Pacific: Weight Loss Market for Services & Programs, by Type, 2024-2036 (USD Million)
Table 420. Rest of Asia-Pacific: Weight Loss Market, by Drug Class, 2024-2036 (USD Million)
Table 421. Rest of Asia-Pacific: Weight Loss Market for GLP-1 Receptor Agonists, by Type, 2024-2036 (USD Million)
Table 422. Rest of Asia-Pacific: Weight Loss Market for Dual & Triple Incretin Agonists, by Type, 2024-2036 (USD Million)
Table 423. Rest of Asia-Pacific: Weight Loss Market for Conventional Anti-Obesity Agents, by Type, 2024-2036 (USD Million)
Table 424. Rest of Asia-Pacific: Weight Loss Market, by Route of Administration, 2024-2036 (USD Million)
Table 425. Rest of Asia-Pacific: Weight Loss Market for Injectable, by Type, 2024-2036 (USD Million)
Table 426. Rest of Asia-Pacific: Weight Loss Market for Oral, by Type, 2024-2036 (USD Million)
Table 427. Rest of Asia-Pacific: Weight Loss Market, by Intervention Setting, 2024-2036 (USD Million)
Table 428. Rest of Asia-Pacific: Weight Loss Market, by Payer, 2024-2036 (USD Million)
Table 429. Rest of Asia-Pacific: Weight Loss Market for Public Insurance & Government Programs, by Type, 2024-2036 (USD Million)
Table 430. Rest of Asia-Pacific: Weight Loss Market, by Consumer Demographic, 2024-2036 (USD Million)
Table 431. Rest of Asia-Pacific: Weight Loss Market, by Distribution Channel, 2024-2036 (USD Million)
Table 432. Latin America: Weight Loss Market, by Country, 2024-2036 (USD Million)
Table 433. Latin America: Weight Loss Market, by Offering, 2024-2036 (USD Million)
Table 434. Latin America: Weight Loss Market for Weight Loss Pharmacotherapy, by Type, 2024-2036 (USD Million)
Table 435. Latin America: Weight Loss Market for Nutrition & Meal Replacement, by Type, 2024-2036 (USD Million)
Table 436. Latin America: Weight Loss Market for Devices & Surgical Products, by Type, 2024-2036 (USD Million)
Table 437. Latin America: Weight Loss Market for Services & Programs, by Type, 2024-2036 (USD Million)
Table 438. Latin America: Weight Loss Market, by Drug Class, 2024-2036 (USD Million)
Table 439. Latin America: Weight Loss Market for GLP-1 Receptor Agonists, by Type, 2024-2036 (USD Million)
Table 440. Latin America: Weight Loss Market for Dual & Triple Incretin Agonists, by Type, 2024-2036 (USD Million)
Table 441. Latin America: Weight Loss Market for Conventional Anti-Obesity Agents, by Type, 2024-2036 (USD Million)
Table 442. Latin America: Weight Loss Market, by Route of Administration, 2024-2036 (USD Million)
Table 443. Latin America: Weight Loss Market for Injectable, by Type, 2024-2036 (USD Million)
Table 444. Latin America: Weight Loss Market for Oral, by Type, 2024-2036 (USD Million)
Table 445. Latin America: Weight Loss Market, by Intervention Setting, 2024-2036 (USD Million)
Table 446. Latin America: Weight Loss Market, by Payer, 2024-2036 (USD Million)
Table 447. Latin America: Weight Loss Market for Public Insurance & Government Programs, by Type, 2024-2036 (USD Million)
Table 448. Latin America: Weight Loss Market, by Consumer Demographic, 2024-2036 (USD Million)
Table 449. Latin America: Weight Loss Market, by Distribution Channel, 2024-2036 (USD Million)
Table 450. Brazil: Weight Loss Market, by Offering, 2024-2036 (USD Million)
Table 451. Brazil: Weight Loss Market for Weight Loss Pharmacotherapy, by Type, 2024-2036 (USD Million)
Table 452. Brazil: Weight Loss Market for Nutrition & Meal Replacement, by Type, 2024-2036 (USD Million)
Table 453. Brazil: Weight Loss Market for Devices & Surgical Products, by Type, 2024-2036 (USD Million)
Table 454. Brazil: Weight Loss Market for Services & Programs, by Type, 2024-2036 (USD Million)
Table 455. Brazil: Weight Loss Market, by Drug Class, 2024-2036 (USD Million)
Table 456. Brazil: Weight Loss Market for GLP-1 Receptor Agonists, by Type, 2024-2036 (USD Million)
Table 457. Brazil: Weight Loss Market for Dual & Triple Incretin Agonists, by Type, 2024-2036 (USD Million)
Table 458. Brazil: Weight Loss Market for Conventional Anti-Obesity Agents, by Type, 2024-2036 (USD Million)
Table 459. Brazil: Weight Loss Market, by Route of Administration, 2024-2036 (USD Million)
Table 460. Brazil: Weight Loss Market for Injectable, by Type, 2024-2036 (USD Million)
Table 461. Brazil: Weight Loss Market for Oral, by Type, 2024-2036 (USD Million)
Table 462. Brazil: Weight Loss Market, by Intervention Setting, 2024-2036 (USD Million)
Table 463. Brazil: Weight Loss Market, by Payer, 2024-2036 (USD Million)
Table 464. Brazil: Weight Loss Market for Public Insurance & Government Programs, by Type, 2024-2036 (USD Million)
Table 465. Brazil: Weight Loss Market, by Consumer Demographic, 2024-2036 (USD Million)
Table 466. Brazil: Weight Loss Market, by Distribution Channel, 2024-2036 (USD Million)
Table 467. Mexico: Weight Loss Market, by Offering, 2024-2036 (USD Million)
Table 468. Mexico: Weight Loss Market for Weight Loss Pharmacotherapy, by Type, 2024-2036 (USD Million)
Table 469. Mexico: Weight Loss Market for Nutrition & Meal Replacement, by Type, 2024-2036 (USD Million)
Table 470. Mexico: Weight Loss Market for Devices & Surgical Products, by Type, 2024-2036 (USD Million)
Table 471. Mexico: Weight Loss Market for Services & Programs, by Type, 2024-2036 (USD Million)
Table 472. Mexico: Weight Loss Market, by Drug Class, 2024-2036 (USD Million)
Table 473. Mexico: Weight Loss Market for GLP-1 Receptor Agonists, by Type, 2024-2036 (USD Million)
Table 474. Mexico: Weight Loss Market for Dual & Triple Incretin Agonists, by Type, 2024-2036 (USD Million)
Table 475. Mexico: Weight Loss Market for Conventional Anti-Obesity Agents, by Type, 2024-2036 (USD Million)
Table 476. Mexico: Weight Loss Market, by Route of Administration, 2024-2036 (USD Million)
Table 477. Mexico: Weight Loss Market for Injectable, by Type, 2024-2036 (USD Million)
Table 478. Mexico: Weight Loss Market for Oral, by Type, 2024-2036 (USD Million)
Table 479. Mexico: Weight Loss Market, by Intervention Setting, 2024-2036 (USD Million)
Table 480. Mexico: Weight Loss Market, by Payer, 2024-2036 (USD Million)
Table 481. Mexico: Weight Loss Market for Public Insurance & Government Programs, by Type, 2024-2036 (USD Million)
Table 482. Mexico: Weight Loss Market, by Consumer Demographic, 2024-2036 (USD Million)
Table 483. Mexico: Weight Loss Market, by Distribution Channel, 2024-2036 (USD Million)
Table 484. Argentina: Weight Loss Market, by Offering, 2024-2036 (USD Million)
Table 485. Argentina: Weight Loss Market for Weight Loss Pharmacotherapy, by Type, 2024-2036 (USD Million)
Table 486. Argentina: Weight Loss Market for Nutrition & Meal Replacement, by Type, 2024-2036 (USD Million)
Table 487. Argentina: Weight Loss Market for Devices & Surgical Products, by Type, 2024-2036 (USD Million)
Table 488. Argentina: Weight Loss Market for Services & Programs, by Type, 2024-2036 (USD Million)
Table 489. Argentina: Weight Loss Market, by Drug Class, 2024-2036 (USD Million)
Table 490. Argentina: Weight Loss Market for GLP-1 Receptor Agonists, by Type, 2024-2036 (USD Million)
Table 491. Argentina: Weight Loss Market for Dual & Triple Incretin Agonists, by Type, 2024-2036 (USD Million)
Table 492. Argentina: Weight Loss Market for Conventional Anti-Obesity Agents, by Type, 2024-2036 (USD Million)
Table 493. Argentina: Weight Loss Market, by Route of Administration, 2024-2036 (USD Million)
Table 494. Argentina: Weight Loss Market for Injectable, by Type, 2024-2036 (USD Million)
Table 495. Argentina: Weight Loss Market for Oral, by Type, 2024-2036 (USD Million)
Table 496. Argentina: Weight Loss Market, by Intervention Setting, 2024-2036 (USD Million)
Table 497. Argentina: Weight Loss Market, by Payer, 2024-2036 (USD Million)
Table 498. Argentina: Weight Loss Market for Public Insurance & Government Programs, by Type, 2024-2036 (USD Million)
Table 499. Argentina: Weight Loss Market, by Consumer Demographic, 2024-2036 (USD Million)
Table 500. Argentina: Weight Loss Market, by Distribution Channel, 2024-2036 (USD Million)
Table 501. Colombia: Weight Loss Market, by Offering, 2024-2036 (USD Million)
Table 502. Colombia: Weight Loss Market for Weight Loss Pharmacotherapy, by Type, 2024-2036 (USD Million)
Table 503. Colombia: Weight Loss Market for Nutrition & Meal Replacement, by Type, 2024-2036 (USD Million)
Table 504. Colombia: Weight Loss Market for Devices & Surgical Products, by Type, 2024-2036 (USD Million)
Table 505. Colombia: Weight Loss Market for Services & Programs, by Type, 2024-2036 (USD Million)
Table 506. Colombia: Weight Loss Market, by Drug Class, 2024-2036 (USD Million)
Table 507. Colombia: Weight Loss Market for GLP-1 Receptor Agonists, by Type, 2024-2036 (USD Million)
Table 508. Colombia: Weight Loss Market for Dual & Triple Incretin Agonists, by Type, 2024-2036 (USD Million)
Table 509. Colombia: Weight Loss Market for Conventional Anti-Obesity Agents, by Type, 2024-2036 (USD Million)
Table 510. Colombia: Weight Loss Market, by Route of Administration, 2024-2036 (USD Million)
Table 511. Colombia: Weight Loss Market for Injectable, by Type, 2024-2036 (USD Million)
Table 512. Colombia: Weight Loss Market for Oral, by Type, 2024-2036 (USD Million)
Table 513. Colombia: Weight Loss Market, by Intervention Setting, 2024-2036 (USD Million)
Table 514. Colombia: Weight Loss Market, by Payer, 2024-2036 (USD Million)
Table 515. Colombia: Weight Loss Market for Public Insurance & Government Programs, by Type, 2024-2036 (USD Million)
Table 516. Colombia: Weight Loss Market, by Consumer Demographic, 2024-2036 (USD Million)
Table 517. Colombia: Weight Loss Market, by Distribution Channel, 2024-2036 (USD Million)
Table 518. Rest of Latin America: Weight Loss Market, by Offering, 2024-2036 (USD Million)
Table 519. Rest of Latin America: Weight Loss Market for Weight Loss Pharmacotherapy, by Type, 2024-2036 (USD Million)
Table 520. Rest of Latin America: Weight Loss Market for Nutrition & Meal Replacement, by Type, 2024-2036 (USD Million)
Table 521. Rest of Latin America: Weight Loss Market for Devices & Surgical Products, by Type, 2024-2036 (USD Million)
Table 522. Rest of Latin America: Weight Loss Market for Services & Programs, by Type, 2024-2036 (USD Million)
Table 523. Rest of Latin America: Weight Loss Market, by Drug Class, 2024-2036 (USD Million)
Table 524. Rest of Latin America: Weight Loss Market for GLP-1 Receptor Agonists, by Type, 2024-2036 (USD Million)
Table 525. Rest of Latin America: Weight Loss Market for Dual & Triple Incretin Agonists, by Type, 2024-2036 (USD Million)
Table 526. Rest of Latin America: Weight Loss Market for Conventional Anti-Obesity Agents, by Type, 2024-2036 (USD Million)
Table 527. Rest of Latin America: Weight Loss Market, by Route of Administration, 2024-2036 (USD Million)
Table 528. Rest of Latin America: Weight Loss Market for Injectable, by Type, 2024-2036 (USD Million)
Table 529. Rest of Latin America: Weight Loss Market for Oral, by Type, 2024-2036 (USD Million)
Table 530. Rest of Latin America: Weight Loss Market, by Intervention Setting, 2024-2036 (USD Million)
Table 531. Rest of Latin America: Weight Loss Market, by Payer, 2024-2036 (USD Million)
Table 532. Rest of Latin America: Weight Loss Market for Public Insurance & Government Programs, by Type, 2024-2036 (USD Million)
Table 533. Rest of Latin America: Weight Loss Market, by Consumer Demographic, 2024-2036 (USD Million)
Table 534. Rest of Latin America: Weight Loss Market, by Distribution Channel, 2024-2036 (USD Million)
Table 535. Middle East & Africa: Weight Loss Market, by Country, 2024-2036 (USD Million)
Table 536. Middle East & Africa: Weight Loss Market, by Offering, 2024-2036 (USD Million)
Table 537. Middle East & Africa: Weight Loss Market for Weight Loss Pharmacotherapy, by Type, 2024-2036 (USD Million)
Table 538. Middle East & Africa: Weight Loss Market for Nutrition & Meal Replacement, by Type, 2024-2036 (USD Million)
Table 539. Middle East & Africa: Weight Loss Market for Devices & Surgical Products, by Type, 2024-2036 (USD Million)
Table 540. Middle East & Africa: Weight Loss Market for Services & Programs, by Type, 2024-2036 (USD Million)
Table 541. Middle East & Africa: Weight Loss Market, by Drug Class, 2024-2036 (USD Million)
Table 542. Middle East & Africa: Weight Loss Market for GLP-1 Receptor Agonists, by Type, 2024-2036 (USD Million)
Table 543. Middle East & Africa: Weight Loss Market for Dual & Triple Incretin Agonists, by Type, 2024-2036 (USD Million)
Table 544. Middle East & Africa: Weight Loss Market for Conventional Anti-Obesity Agents, by Type, 2024-2036 (USD Million)
Table 545. Middle East & Africa: Weight Loss Market, by Route of Administration, 2024-2036 (USD Million)
Table 546. Middle East & Africa: Weight Loss Market for Injectable, by Type, 2024-2036 (USD Million)
Table 547. Middle East & Africa: Weight Loss Market for Oral, by Type, 2024-2036 (USD Million)
Table 548. Middle East & Africa: Weight Loss Market, by Intervention Setting, 2024-2036 (USD Million)
Table 549. Middle East & Africa: Weight Loss Market, by Payer, 2024-2036 (USD Million)
Table 550. Middle East & Africa: Weight Loss Market for Public Insurance & Government Programs, by Type, 2024-2036 (USD Million)
Table 551. Middle East & Africa: Weight Loss Market, by Consumer Demographic, 2024-2036 (USD Million)
Table 552. Middle East & Africa: Weight Loss Market, by Distribution Channel, 2024-2036 (USD Million)
Table 553. Saudi Arabia: Weight Loss Market, by Offering, 2024-2036 (USD Million)
Table 554. Saudi Arabia: Weight Loss Market for Weight Loss Pharmacotherapy, by Type, 2024-2036 (USD Million)
Table 555. Saudi Arabia: Weight Loss Market for Nutrition & Meal Replacement, by Type, 2024-2036 (USD Million)
Table 556. Saudi Arabia: Weight Loss Market for Devices & Surgical Products, by Type, 2024-2036 (USD Million)
Table 557. Saudi Arabia: Weight Loss Market for Services & Programs, by Type, 2024-2036 (USD Million)
Table 558. Saudi Arabia: Weight Loss Market, by Drug Class, 2024-2036 (USD Million)
Table 559. Saudi Arabia: Weight Loss Market for GLP-1 Receptor Agonists, by Type, 2024-2036 (USD Million)
Table 560. Saudi Arabia: Weight Loss Market for Dual & Triple Incretin Agonists, by Type, 2024-2036 (USD Million)
Table 561. Saudi Arabia: Weight Loss Market for Conventional Anti-Obesity Agents, by Type, 2024-2036 (USD Million)
Table 562. Saudi Arabia: Weight Loss Market, by Route of Administration, 2024-2036 (USD Million)
Table 563. Saudi Arabia: Weight Loss Market for Injectable, by Type, 2024-2036 (USD Million)
Table 564. Saudi Arabia: Weight Loss Market for Oral, by Type, 2024-2036 (USD Million)
Table 565. Saudi Arabia: Weight Loss Market, by Intervention Setting, 2024-2036 (USD Million)
Table 566. Saudi Arabia: Weight Loss Market, by Payer, 2024-2036 (USD Million)
Table 567. Saudi Arabia: Weight Loss Market for Public Insurance & Government Programs, by Type, 2024-2036 (USD Million)
Table 568. Saudi Arabia: Weight Loss Market, by Consumer Demographic, 2024-2036 (USD Million)
Table 569. Saudi Arabia: Weight Loss Market, by Distribution Channel, 2024-2036 (USD Million)
Table 570. UAE: Weight Loss Market, by Offering, 2024-2036 (USD Million)
Table 571. UAE: Weight Loss Market for Weight Loss Pharmacotherapy, by Type, 2024-2036 (USD Million)
Table 572. UAE: Weight Loss Market for Nutrition & Meal Replacement, by Type, 2024-2036 (USD Million)
Table 573. UAE: Weight Loss Market for Devices & Surgical Products, by Type, 2024-2036 (USD Million)
Table 574. UAE: Weight Loss Market for Services & Programs, by Type, 2024-2036 (USD Million)
Table 575. UAE: Weight Loss Market, by Drug Class, 2024-2036 (USD Million)
Table 576. UAE: Weight Loss Market for GLP-1 Receptor Agonists, by Type, 2024-2036 (USD Million)
Table 577. UAE: Weight Loss Market for Dual & Triple Incretin Agonists, by Type, 2024-2036 (USD Million)
Table 578. UAE: Weight Loss Market for Conventional Anti-Obesity Agents, by Type, 2024-2036 (USD Million)
Table 579. UAE: Weight Loss Market, by Route of Administration, 2024-2036 (USD Million)
Table 580. UAE: Weight Loss Market for Injectable, by Type, 2024-2036 (USD Million)
Table 581. UAE: Weight Loss Market for Oral, by Type, 2024-2036 (USD Million)
Table 582. UAE: Weight Loss Market, by Intervention Setting, 2024-2036 (USD Million)
Table 583. UAE: Weight Loss Market, by Payer, 2024-2036 (USD Million)
Table 584. UAE: Weight Loss Market for Public Insurance & Government Programs, by Type, 2024-2036 (USD Million)
Table 585. UAE: Weight Loss Market, by Consumer Demographic, 2024-2036 (USD Million)
Table 586. UAE: Weight Loss Market, by Distribution Channel, 2024-2036 (USD Million)
Table 587. Kuwait: Weight Loss Market, by Offering, 2024-2036 (USD Million)
Table 588. Kuwait: Weight Loss Market for Weight Loss Pharmacotherapy, by Type, 2024-2036 (USD Million)
Table 589. Kuwait: Weight Loss Market for Nutrition & Meal Replacement, by Type, 2024-2036 (USD Million)
Table 590. Kuwait: Weight Loss Market for Devices & Surgical Products, by Type, 2024-2036 (USD Million)
Table 591. Kuwait: Weight Loss Market for Services & Programs, by Type, 2024-2036 (USD Million)
Table 592. Kuwait: Weight Loss Market, by Drug Class, 2024-2036 (USD Million)
Table 593. Kuwait: Weight Loss Market for GLP-1 Receptor Agonists, by Type, 2024-2036 (USD Million)
Table 594. Kuwait: Weight Loss Market for Dual & Triple Incretin Agonists, by Type, 2024-2036 (USD Million)
Table 595. Kuwait: Weight Loss Market for Conventional Anti-Obesity Agents, by Type, 2024-2036 (USD Million)
Table 596. Kuwait: Weight Loss Market, by Route of Administration, 2024-2036 (USD Million)
Table 597. Kuwait: Weight Loss Market for Injectable, by Type, 2024-2036 (USD Million)
Table 598. Kuwait: Weight Loss Market for Oral, by Type, 2024-2036 (USD Million)
Table 599. Kuwait: Weight Loss Market, by Intervention Setting, 2024-2036 (USD Million)
Table 600. Kuwait: Weight Loss Market, by Payer, 2024-2036 (USD Million)
Table 601. Kuwait: Weight Loss Market for Public Insurance & Government Programs, by Type, 2024-2036 (USD Million)
Table 602. Kuwait: Weight Loss Market, by Consumer Demographic, 2024-2036 (USD Million)
Table 603. Kuwait: Weight Loss Market, by Distribution Channel, 2024-2036 (USD Million)
Table 604. Qatar: Weight Loss Market, by Offering, 2024-2036 (USD Million)
Table 605. Qatar: Weight Loss Market for Weight Loss Pharmacotherapy, by Type, 2024-2036 (USD Million)
Table 606. Qatar: Weight Loss Market for Nutrition & Meal Replacement, by Type, 2024-2036 (USD Million)
Table 607. Qatar: Weight Loss Market for Devices & Surgical Products, by Type, 2024-2036 (USD Million)
Table 608. Qatar: Weight Loss Market for Services & Programs, by Type, 2024-2036 (USD Million)
Table 609. Qatar: Weight Loss Market, by Drug Class, 2024-2036 (USD Million)
Table 610. Qatar: Weight Loss Market for GLP-1 Receptor Agonists, by Type, 2024-2036 (USD Million)
Table 611. Qatar: Weight Loss Market for Dual & Triple Incretin Agonists, by Type, 2024-2036 (USD Million)
Table 612. Qatar: Weight Loss Market for Conventional Anti-Obesity Agents, by Type, 2024-2036 (USD Million)
Table 613. Qatar: Weight Loss Market, by Route of Administration, 2024-2036 (USD Million)
Table 614. Qatar: Weight Loss Market for Injectable, by Type, 2024-2036 (USD Million)
Table 615. Qatar: Weight Loss Market for Oral, by Type, 2024-2036 (USD Million)
Table 616. Qatar: Weight Loss Market, by Intervention Setting, 2024-2036 (USD Million)
Table 617. Qatar: Weight Loss Market, by Payer, 2024-2036 (USD Million)
Table 618. Qatar: Weight Loss Market for Public Insurance & Government Programs, by Type, 2024-2036 (USD Million)
Table 619. Qatar: Weight Loss Market, by Consumer Demographic, 2024-2036 (USD Million)
Table 620. Qatar: Weight Loss Market, by Distribution Channel, 2024-2036 (USD Million)
Table 621. Israel: Weight Loss Market, by Offering, 2024-2036 (USD Million)
Table 622. Israel: Weight Loss Market for Weight Loss Pharmacotherapy, by Type, 2024-2036 (USD Million)
Table 623. Israel: Weight Loss Market for Nutrition & Meal Replacement, by Type, 2024-2036 (USD Million)
Table 624. Israel: Weight Loss Market for Devices & Surgical Products, by Type, 2024-2036 (USD Million)
Table 625. Israel: Weight Loss Market for Services & Programs, by Type, 2024-2036 (USD Million)
Table 626. Israel: Weight Loss Market, by Drug Class, 2024-2036 (USD Million)
Table 627. Israel: Weight Loss Market for GLP-1 Receptor Agonists, by Type, 2024-2036 (USD Million)
Table 628. Israel: Weight Loss Market for Dual & Triple Incretin Agonists, by Type, 2024-2036 (USD Million)
Table 629. Israel: Weight Loss Market for Conventional Anti-Obesity Agents, by Type, 2024-2036 (USD Million)
Table 630. Israel: Weight Loss Market, by Route of Administration, 2024-2036 (USD Million)
Table 631. Israel: Weight Loss Market for Injectable, by Type, 2024-2036 (USD Million)
Table 632. Israel: Weight Loss Market for Oral, by Type, 2024-2036 (USD Million)
Table 633. Israel: Weight Loss Market, by Intervention Setting, 2024-2036 (USD Million)
Table 634. Israel: Weight Loss Market, by Payer, 2024-2036 (USD Million)
Table 635. Israel: Weight Loss Market for Public Insurance & Government Programs, by Type, 2024-2036 (USD Million)
Table 636. Israel: Weight Loss Market, by Consumer Demographic, 2024-2036 (USD Million)
Table 637. Israel: Weight Loss Market, by Distribution Channel, 2024-2036 (USD Million)
Table 638. South Africa: Weight Loss Market, by Offering, 2024-2036 (USD Million)
Table 639. South Africa: Weight Loss Market for Weight Loss Pharmacotherapy, by Type, 2024-2036 (USD Million)
Table 640. South Africa: Weight Loss Market for Nutrition & Meal Replacement, by Type, 2024-2036 (USD Million)
Table 641. South Africa: Weight Loss Market for Devices & Surgical Products, by Type, 2024-2036 (USD Million)
Table 642. South Africa: Weight Loss Market for Services & Programs, by Type, 2024-2036 (USD Million)
Table 643. South Africa: Weight Loss Market, by Drug Class, 2024-2036 (USD Million)
Table 644. South Africa: Weight Loss Market for GLP-1 Receptor Agonists, by Type, 2024-2036 (USD Million)
Table 645. South Africa: Weight Loss Market for Dual & Triple Incretin Agonists, by Type, 2024-2036 (USD Million)
Table 646. South Africa: Weight Loss Market for Conventional Anti-Obesity Agents, by Type, 2024-2036 (USD Million)
Table 647. South Africa: Weight Loss Market, by Route of Administration, 2024-2036 (USD Million)
Table 648. South Africa: Weight Loss Market for Injectable, by Type, 2024-2036 (USD Million)
Table 649. South Africa: Weight Loss Market for Oral, by Type, 2024-2036 (USD Million)
Table 650. South Africa: Weight Loss Market, by Intervention Setting, 2024-2036 (USD Million)
Table 651. South Africa: Weight Loss Market, by Payer, 2024-2036 (USD Million)
Table 652. South Africa: Weight Loss Market for Public Insurance & Government Programs, by Type, 2024-2036 (USD Million)
Table 653. South Africa: Weight Loss Market, by Consumer Demographic, 2024-2036 (USD Million)
Table 654. South Africa: Weight Loss Market, by Distribution Channel, 2024-2036 (USD Million)
Table 655. Rest of Middle East & Africa: Weight Loss Market, by Offering, 2024-2036 (USD Million)
Table 656. Rest of Middle East & Africa: Weight Loss Market for Weight Loss Pharmacotherapy, by Type, 2024-2036 (USD Million)
Table 657. Rest of Middle East & Africa: Weight Loss Market for Nutrition & Meal Replacement, by Type, 2024-2036 (USD Million)
Table 658. Rest of Middle East & Africa: Weight Loss Market for Devices & Surgical Products, by Type, 2024-2036 (USD Million)
Table 659. Rest of Middle East & Africa: Weight Loss Market for Services & Programs, by Type, 2024-2036 (USD Million)
Table 660. Rest of Middle East & Africa: Weight Loss Market, by Drug Class, 2024-2036 (USD Million)
Table 661. Rest of Middle East & Africa: Weight Loss Market for GLP-1 Receptor Agonists, by Type, 2024-2036 (USD Million)
Table 662. Rest of Middle East & Africa: Weight Loss Market for Dual & Triple Incretin Agonists, by Type, 2024-2036 (USD Million)
Table 663. Rest of Middle East & Africa: Weight Loss Market for Conventional Anti-Obesity Agents, by Type, 2024-2036 (USD Million)
Table 664. Rest of Middle East & Africa: Weight Loss Market, by Route of Administration, 2024-2036 (USD Million)
Table 665. Rest of Middle East & Africa: Weight Loss Market for Injectable, by Type, 2024-2036 (USD Million)
Table 666. Rest of Middle East & Africa: Weight Loss Market for Oral, by Type, 2024-2036 (USD Million)
Table 667. Rest of Middle East & Africa: Weight Loss Market, by Intervention Setting, 2024-2036 (USD Million)
Table 668. Rest of Middle East & Africa: Weight Loss Market, by Payer, 2024-2036 (USD Million)
Table 669. Rest of Middle East & Africa: Weight Loss Market for Public Insurance & Government Programs, by Type, 2024-2036 (USD Million)
Table 670. Rest of Middle East & Africa: Weight Loss Market, by Consumer Demographic, 2024-2036 (USD Million)
Table 671. Rest of Middle East & Africa: Weight Loss Market, by Distribution Channel, 2024-2036 (USD Million)
Table 672. Weight Loss Market: Key Growth Strategies Adopted by Leading Players (2024-2026)
Table 673. Weight Loss Market: Strategic Developments, by Company (2024-2026)
Table 674. Weight Loss Market: Competitive Benchmarking
Table 675. Weight Loss Market: Market Share/Ranking Analysis, by Key Player (2025)
Table 676. Novo Nordisk A/S: Product Portfolio
Table 677. Novo Nordisk A/S: Strategic Developments
Table 678. Eli Lilly and Company: Product Portfolio
Table 679. Eli Lilly and Company: Strategic Developments
Table 680. Currax Pharmaceuticals LLC: Product Portfolio
Table 681. Currax Pharmaceuticals LLC: Strategic Developments
Table 682. VIVUS LLC: Product Portfolio
Table 683. VIVUS LLC: Strategic Developments
Table 684. Boehringer Ingelheim International GmbH: Product Portfolio
Table 685. Boehringer Ingelheim International GmbH: Strategic Developments
Table 686. Amgen Inc.: Product Portfolio
Table 687. Amgen Inc.: Strategic Developments
Table 688. Pfizer Inc.: Product Portfolio
Table 689. Pfizer Inc.: Strategic Developments
Table 690. AstraZeneca PLC: Product Portfolio
Table 691. AstraZeneca PLC: Strategic Developments
Table 692. Roche Holding AG: Product Portfolio
Table 693. Roche Holding AG: Strategic Developments
Table 694. Herbalife Ltd.: Product Portfolio
Table 695. Herbalife Ltd.: Strategic Developments
Table 696. Medifast, Inc.: Product Portfolio
Table 697. Medifast, Inc.: Strategic Developments
Table 698. Nestlé S.A.: Product Portfolio
Table 699. Nestlé S.A.: Strategic Developments
Table 700. Abbott Laboratories: Product Portfolio
Table 701. Abbott Laboratories: Strategic Developments
Table 702. Danone S.A.: Product Portfolio
Table 703. Danone S.A.: Strategic Developments
Table 704. Glanbia plc: Product Portfolio
Table 705. Glanbia plc: Strategic Developments
Table 706. WW International, Inc.: Product Portfolio
Table 707. WW International, Inc.: Strategic Developments
Table 708. Hims & Hers Health, Inc.: Product Portfolio
Table 709. Hims & Hers Health, Inc.: Strategic Developments
Table 710. Noom, Inc.: Product Portfolio
Table 711. Noom, Inc.: Strategic Developments
Table 712. Medtronic plc: Product Portfolio
Table 713. Medtronic plc: Strategic Developments
Table 714. Johnson & Johnson MedTech: Product Portfolio
Table 715. Johnson & Johnson MedTech: Strategic Developments
Table 716. Apollo Endosurgery (Boston Scientific): Product Portfolio
Table 717. Apollo Endosurgery (Boston Scientific): Strategic Developments
Table 718. Allurion Technologies, Inc.: Product Portfolio
Table 719. Allurion Technologies, Inc.: Strategic Developments
Table 720. Available Customization Options
Table 721. Available Related Reports

LIST OF FIGURES

Figure 1. Research Process
Figure 2. Key Secondary Sources
Figure 3. Primary Research Techniques
Figure 4. Key Executives Interviewed
Figure 5. Breakdown of Primary Interviews (Supply-Side & Demand-Side)
Figure 6. Market Sizing and Growth Forecast Approach
Figure 7. Executive Summary: Global Weight Loss Market Size, 2024-2036 (USD Million)
Figure 8. Executive Summary: Global Weight Loss Market, by Offering, 2026 vs. 2036 (USD Million)
Figure 9. Executive Summary: Global Weight Loss Market, by Drug Class, 2026 vs. 2036 (USD Million)
Figure 10. Executive Summary: Global Weight Loss Market, by Route of Administration, 2026 vs. 2036 (USD Million)
Figure 11. Executive Summary: Global Weight Loss Market, by Intervention Setting, 2026 vs. 2036 (USD Million)
Figure 12. Executive Summary: Global Weight Loss Market, by Payer, 2026 vs. 2036 (USD Million)
Figure 13. Executive Summary: Global Weight Loss Market, by Consumer Demographic, 2026 vs. 2036 (USD Million)
Figure 14. Executive Summary: Global Weight Loss Market, by Distribution Channel, 2026 vs. 2036 (USD Million)
Figure 15. Executive Summary: Global Weight Loss Market, by Region, 2026 vs. 2036 (USD Million)
Figure 16. Executive Summary: Competitive Landscape of the Weight Loss Market
Figure 17. Factors Impacting the Growth of the Weight Loss Market
Figure 18. Weight Loss Market Ecosystem
Figure 19. Obesity Treatment Pathway: Lifestyle, Nutrition, Pharmacotherapy, Devices and Surgery
Figure 20. Incretin Mechanism Landscape (GLP-1, GIP, Glucagon, Amylin)
Figure 21. GLP-1 Prescriptions versus Bariatric Surgery Volumes in Severe Obesity, 2018-2025
Figure 22. Value Chain Analysis: Weight Loss Market
Figure 23. Global Weight Loss Market, by Offering, 2026 vs. 2036 (USD Million)
Figure 24. Global Weight Loss Market, by Drug Class, 2026 vs. 2036 (USD Million)
Figure 25. Global Weight Loss Market, by Route of Administration, 2026 vs. 2036 (USD Million)
Figure 26. Global Weight Loss Market, by Intervention Setting, 2026 vs. 2036 (USD Million)
Figure 27. Global Weight Loss Market, by Payer, 2026 vs. 2036 (USD Million)
Figure 28. Global Weight Loss Market, by Consumer Demographic, 2026 vs. 2036 (USD Million)
Figure 29. Global Weight Loss Market, by Distribution Channel, 2026 vs. 2036 (USD Million)
Figure 30. Global Weight Loss Market, by Region, 2026 vs. 2036 (USD Million)
Figure 31. North America: Weight Loss Market Snapshot
Figure 32. Europe: Weight Loss Market Snapshot
Figure 33. Asia-Pacific: Weight Loss Market Snapshot
Figure 34. Latin America: Weight Loss Market Snapshot
Figure 35. Middle East & Africa: Weight Loss Market Snapshot
Figure 36. Key Growth Strategies Adopted by Leading Players in the Weight Loss Market (2024-2026)
Figure 37. Weight Loss Market: Competitive Dashboard
Figure 38. Weight Loss Market Share/Ranking Analysis, by Key Player (2025)
Figure 39. Novo Nordisk A/S: SWOT Analysis
Figure 40. Eli Lilly and Company: SWOT Analysis
Figure 41. Currax Pharmaceuticals LLC: SWOT Analysis
Figure 42. VIVUS LLC: SWOT Analysis
Figure 43. Boehringer Ingelheim International GmbH: SWOT Analysis
Figure 44. Amgen Inc.: SWOT Analysis
Figure 45. Pfizer Inc.: SWOT Analysis
Figure 46. AstraZeneca PLC: SWOT Analysis
Figure 47. Roche Holding AG: SWOT Analysis
Figure 48. Herbalife Ltd.: SWOT Analysis
Figure 49. Medifast, Inc.: SWOT Analysis
Figure 50. Nestlé S.A.: SWOT Analysis
Figure 51. Abbott Laboratories: SWOT Analysis
Figure 52. Danone S.A.: SWOT Analysis
Figure 53. Glanbia plc: SWOT Analysis
Figure 54. WW International, Inc.: SWOT Analysis
Figure 55. Hims & Hers Health, Inc.: SWOT Analysis
Figure 56. Noom, Inc.: SWOT Analysis
Figure 57. Medtronic plc: SWOT Analysis
Figure 58. Johnson & Johnson MedTech: SWOT Analysis
Figure 59. Apollo Endosurgery (Boston Scientific): SWOT Analysis
Figure 60. Allurion Technologies, Inc.: SWOT Analysis

Companies Mentioned

Novo Nordisk A/S
Eli Lilly and Company
Currax Pharmaceuticals LLC
VIVUS LLC
Boehringer Ingelheim International GmbH
Amgen Inc.
Pfizer Inc.
AstraZeneca PLC
Roche Holding AG
Herbalife Ltd.
Medifast, Inc.
Nestlé S.A.
Abbott Laboratories
Danone S.A.
Glanbia plc
WW International, Inc.
Hims & Hers Health, Inc.
Noom, Inc.
Medtronic plc
Johnson & Johnson MedTech
Apollo Endosurgery
Allurion Technologies, Inc.

License	Format	Properties	Price
SINGLE USER LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is a single user license, allowing one user access to the product.	€3848EUR$4,175USD£3,242GBP
1 - 5 USER LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is a 1-5 user license, allowing up to five users have access to the product.	€5415EUR$5,875USD£4,562GBP
ENTERPRISE LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is an enterprise license, allowing all employees within your organization access to the product.	€7259EUR$7,875USD£6,115GBP

Weight Loss Market Size, Share, Forecast & Trends Analysis - Global Forecast to 2036

Market Dynamics

Segment Analysis

Regional Analysis

Competitive Landscape

How This Report Helps

Key Questions Answered

Table of Contents

Companies Mentioned

Market Dynamics

Segment Analysis

Regional Analysis

Competitive Landscape

How This Report Helps

Key Questions Answered

Table of Contents

Companies Mentioned

Related Topics

Related Reports

UK Prescription Weight Loss Medications Market Size, Share & Trends Analysis Report by Product (Incretin-Based Therapies for Weight Management), Route of Administration (Injectable, Oral), Prescribing Channel with Growth Forecasts, 2026-2033

Nutraceutical Excipients Market By Type (Fillers, Diluents, Coating Agents, Binder, Disintegrants), End Products (Protein and Amino Acids, Vitamin, Minerals, Omega 3 Fatty Acids, And Others) - Global Forecast to 2036

Haematococcus Pluvialis Market - Global Forecast to 2036

GLP-1 Agonists Weight Loss Drugs Market Size, Share & Trends Analysis by Drugs (Semaglutide (Wegovy), Tirzepatide (Zepbound)), Route of Administration, Distribution Channel, and Region with Growth Forecasts, 2025-2030

GLP-1 Targeted Peptide Weight Loss Drugs Market - Global Forecast 2025-2030